Study ID: [REMOVED]
Title: A Phase 2b, Randomized, Multicenter, Double-blind, Placebo-controlled, 
Multiple-dose Study to Evaluate the Efficacy, Safety, and Tolerability of 
NDI-034858 in Subjects With Moderate to Severe Plaque Psoriasis
Study Number: 4858-201 (TAK-279)
Document Version and Date: Version 3.0 (04-February-2022)
Certain information within this document has been redacted (i.e., specific content is 
masked irreversibly from view) to protect either personally identifiable information or 
company confidential information. Clinical Study Protocol
Protocol Number 4858- 201 
Protocol Version 3.0: 04 Feb -2022 
Confidential 
1 of 94 A PHASE 2B, RANDOMIZED, MULTICENTER, DOUBLE-BLIND, 
PLACEBO- CONTROLLED, MULTIPLE -DOSE STUDY TO EVALUATE 
THE EFFICACY, SAFETY, AND TOLERABILITY OF NDI -034858 IN 
SUBJECTS WITH MODERATE TO SEVERE PLAQUE PSORIASIS  
PROTOCOL 4
858-201 
FINAL  
AMENDME NT 
2 
VERSION 3.0 
04-Feb-2022
Sponsor: Nimbus Lakshmi, Inc. 
130 Prospect Street, Suite 301 Cambridge, Massachusetts, United States,  02139 
Telephone: 857-999-2009 
Sponsor Medical 
Expert: , MD  
Medical Monitor 
Nimbus Lakshmi, Inc. Telephone: 917 601 0024 
Clinical Research 
Organization: Innovaderm Research Inc.  
3530 Saint- Laurent Boulevard, Suite 300 
Montreal, Quebec, Canada, H2X 2V1 
Telephone: 514-521-4285 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
2 of 94 TABLE OF CONTENTS 
TABLE OF CONTENTS  .................................................................................................................2  
LIST OF TABLES  ...........................................................................................................................6  
LIST OF FIGURE S .........................................................................................................................6  
PROTOCOL VERSION HISTORY ................................................................................................7  
STATEMENT OF COMPLIANCE  ...............................................................................................11  
SIGNATURE PAGE  .....................................................................................................................12  
PRINCIPAL/QUALIFIED INVESTIGATOR SIGNATURE PAGE  ...........................................13  
LIST OF AB BREVIATIONS  ........................................................................................................14  
1. PROTOCOL SUMMARY ..........................................................................................19  
1.1. Synopsis ......................................................................................................................19  
1.2. Study Diagram ............................................................................................................30  
1.3. Schedule of Events .....................................................................................................30  
2. INTRODUCTION  ......................................................................................................35  
2.1. Background .................................................................................................................35  
2.1.1.  Plaque Psoriasis  ..........................................................................................................35  
2.1.2.  NDI-034858 ................................................................................................................35  
2.1.3.  Study Rationale ...........................................................................................................36  
2.1.4.  Clinical Experience  .....................................................................................................36  
2.2. Risk/Benefit Assessment  ............................................................................................40  
2.2.1.  Known Potential Risks ...............................................................................................40  
2.2.2.  Known Potential Benefits ...........................................................................................42  
2.2.3.  Assessment of Risks and Benefits ..............................................................................42  
3. OBJECTIVES AND ENDPOINTS  ............................................................................44  
4. STUDY DESIGN  .......................................................................................................46  
4.1. Overall Design  ............................................................................................................46  
4.2. Study Conduct During the Coronavirus Disease 2019 Pandemic ..............................47  
4.3. Scientific Rationale for Study Design  ........................................................................48  
4.4. Justifica tion for Dose ..................................................................................................49  
4.5. End of Study Definition ..............................................................................................50  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
3 of 94 5. STUDY POPULATION  .............................................................................................51  
5.1. Inclusion Criteria  ........................................................................................................51  
5.2. Exclusion Criteria  .......................................................................................................52  
5.3. Screen Failures  ............................................................................................................56  
6. TREATMENT  ............................................................................................................57  
6.1. Study Treatment Administered  ...................................................................................57  
6.2. Preparation/Handling/Storage/Accountability ............................................................58  
6.2.1.  Preparation/Storage/Handling.....................................................................................58  
6.2.2.  Accountability  .............................................................................................................58  
6.3. Randomization ............................................................................................................58  
6.3.1.  Blinding ......................................................................................................................59  
6.3.2.  Study Treatment Compliance .....................................................................................59  
6.4. Concomitant Therapy .................................................................................................60  
6.4.1.  Permitted Therapies  ....................................................................................................60  
6.4.2.  Prohibited Therapies or Procedures ............................................................................60  
7. DISCONTINUATION AND LOST TO FOLLOW -UP ............................................63  
7.1. Discontinuation from Study Treatment ......................................................................63  
7.2. Discontinuation from Study ........................................................................................64  
7.3. Lost to Follow- Up.......................................................................................................65  
7.4. Study Termination ......................................................................................................66  
8. STUDY ASSESSMENTS AND PROCEDURES  ......................................................67  
8.1. Efficacy Assessments  .................................................................................................67  
8.1.1.  Psoriasis Area and Severity Index  ..............................................................................67  
8.1.2.  Physician â€™s Global Assessment  ..................................................................................67  
8.1.3.   ......................................................................................................67  
8.1.4.   ...................................................................................68  
8.1.5.   .........................................................................................68  
8.2. Quality -of-Life Ass essments/Subject Reported Outcomes  ........................................68  
8.2.1.  Dermatology Life Quality Index Questionnaire .........................................................68  
8.3. Safety and Other Assessments  ....................................................................................68  
8.3.1.  Vital Signs  ..................................................................................................................68  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
4 of 94 8.3.2.  Physical Examination  .................................................................................................68  
8.3.3.  Targeted Physical Examination  ..................................................................................69  
8.3.4.  Clinical Laboratory Tests  ...........................................................................................69  
8.3.5.  Electrocardiogram  .......................................................................................................71  
8.3.6.  Plasma Concentration of NDI-034858 .......................................................................71  
8.3.7.  ................................................................................72  
8.3.8.   ...............................................................................72  
8.3.9.  ...................................................................72  
8.3.10.   ..............................................................72  
8.3.11.  Medical Photography ..................................................................................................73  
8.4. Adverse Events and Serious Adverse Events  .............................................................73  
8.4.1.  Definition of Adverse Event .......................................................................................73  
8.4.2.  Definition of Serious Adverse Event ..........................................................................73  
8.4.3.  Classification of an Adverse Event .............................................................................74  
8.4.4.  Time Peri od and Frequency for Event Assessment and Follow- Up ...........................75  
8.4.5.  Adverse Event Reporting ............................................................................................76  
8.4.6.  Serious Adverse Event Reporting ...............................................................................76  
8.4.7.  Adverse Events of Special Interest  .............................................................................76  
8.4.8.  Potential Drug Induced Liver Injury ...........................................................................78  
8.4.9.  Pregnancy Reporting ..................................................................................................79  
8.4.10.  Overdose .....................................................................................................................79  
9. STATISTICAL CONSIDERATIONS  .......................................................................80  
9.1. Sample Size Determinati on ........................................................................................80  
9.2. Populations for Analyses ............................................................................................80  
9.3. Statistical Analyses  .....................................................................................................80  
9.3.1.  General Approach  .......................................................................................................80  
9.3.2.  Efficacy Analyses  .......................................................................................................81  
9.3.3.  Safety Analyses  ..........................................................................................................81  
9.3.4.  Pharmacokinetic Analyses  ..........................................................................................82  
9.3.5.   .......................................................................................82  
9.3.6.  Other Analyses  ............................................................................................................82  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
5 of 94 9.3.7.  Planned Interim Analyses ...........................................................................................82  
10. REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS  ..................................................................................................83  
10.1.  Local Regulations/Declaration of Helsinki ................................................................83  
10.2.  Ethical Review  ............................................................................................................83  
10.3.  Informed Consent Process ..........................................................................................83  
10.4.  Study Discontinuation and Closure ............................................................................84  
10.5.  Confidentiality and Privacy ........................................................................................84  
10.6.  Clinical Monitoring  ....................................................................................................85  
10.7.  Quality Assurance and Quality Control ......................................................................85  
10.8.  Data Handling and Record Keeping ...........................................................................85  
10.9.  Protocol Deviations ....................................................................................................86  
10.10.  Publication Policy  .......................................................................................................86  
11. REFERENCES  ...........................................................................................................87  
APPENDIX 1.  PARTIAL LIST OF STRONG OR MODERATE INHIBITORS OF 
CYP3A4  ......................................................................................................................89  
APPENDIX 2.  PSORIASIS AREA AND SEVERITY INDEX  .................................................90  
APPENDIX 3.  ........................................................91  
APPENDIX 4.  ..................................................................92  
APPENDIX 5.  DERMATOLOGY LIFE QUALITY INDEX  ....................................................93  
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
Confidential 
6 of 94 LIST OF TABLES  
Table 1:      Schedule of Events .....................................................................................................32 
Table 2:  Potential Risks of NDI -034858 ..................................................................................40  
Table 3:  Study Treat ments  ........................................................................................................57  
Table 4:  Prohibited Therapies or Procedures ............................................................................61  
Table 5:  Physicianâ€™s Global Assessment ..................................................................................67  
Table 6:  Clinical Laboratory Testing ........................................................................................70  
LIST OF FIGURE S 
Figure 1:  Study Diagram ............................................................................................................30  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
7 of 94 PROTOCOL VERSION HISTORY  
Version  Reason for amendment  Main changes to the protocol 
1.0 / 21-May-2021 Initial version  N/A 
2.0-Amendment 1/  
02-Sep-2021 To add clarity and implement 
minor  corrections to text Global: Minor administrative changes to 
the protocol for clarity and to correct 
typographical or minor  errors  were 
implemented.  
 To update the list of secondary 
 efficacy 
endpoints for clarity of intended 
analysi s Section 1.1 and Section 3: The list of 
secondary  efficacy endpoints was 
updated. 
 To clarify or add the 
photographic process for 
biopsies or the photographic 
process for medical photographs 
of full body. Section 1.1; Section 1.3, Table 1; Section  4.1; Section 8.3.11 ; Section 
8.3.11.1 (added section; and Section 8.3.11.2 (added section) : Optional 
medical photographs were added to 
Week 4 visit. It was also clarified that 
for all subjects consenting to biopsy 
collection, the biopsied areas will  be 
photographed and for a subset of 
subjects who consent to the procedure, 
photographs of the full body (front and 
back) will be performed.  
 To clarify the list of highly 
effective methods of 
contraception. Section 1.1 and Section 5.1, Inclusion 
Criterion 7: It was clarified that bilateral 
tubal ligation or occlusion are both 
considered as highly effective methods of contraception. 
 To clarify which systemic 
corticosteroid  treatments are 
exclusionary, prohibited, and/or 
trigger discontinuation of study 
treatment . Section 1.1 and Section 5.2, Exclusion 
Criterion 21; Section 6.4.2, Table 4; and 
Section 7.1: It was clarified that oral, 
intravenous , intramuscular , and 
intralesional injections of corticosteroids 
are prohibited during the study. In 
addition, use of oral, intravenous, or 
intramuscular steroids will lead to 
subject permanent discontinuation  from 
study treatment . 
 To cl arify that non-
live -attenuated vaccines for 
COVID -19 are allowed during 
the study. Section 1.1 and Section 5.2, Exclusion 
Criterion 24; Section 6.4.2, Table 4; and 
Section 7.1: It was clarified that non-
live -attenuated vaccines for COVID -19 
are allowed during the study. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
8 of 94 Version  Reason for amendment  Main changes to the protocol 
 To exclude subjects enrolled in 
previous studies of NDI-034858 
to minimize bias . Section 1.1 and Section 5.2, Exclusion 
Criterion 27: exclusion criteria added. 
 To update or add  unscheduled 
visits , virtual visit s, direct -to-
subject shipping of study 
product, and local lab use 
process es as appropriate, 
including for COVID-19 
mitigation . Section 1.3; Section 4.2; Section 8.3.4.1 
(added section): Unscheduled visit s, 
virtual visits , direct -to-subject shipping 
of study product processes, as well as 
process for  use of local laboratories w ere 
added. 
 To update the criteria for 
mandatory, permanent 
discontinuation from study 
treatment from cytopenia of 
Grade â‰¥2 to cytopenia of 
Grade  â‰¥3. Section 2.2.1, Table 2; Section 7.1; 
Section 8.3.4; and S ection 8.4.7: The 
reason for permanent discontinuation 
from study trea tment due to cytopenia 
was updated f rom cytopenia of Grade â‰¥2 
to cytopenia of Grade â‰¥3. 
 To include a definition of 
noncompliance pertaining to missed doses. Section 6.3.2: The number of doses missed to clearly state the definition of 
noncompliance pertaining to missed 
doses was added .  
 To clarify the process to follow  
if a subject starts  prohibited 
medication or procedure. Section 6.4.2: The process to follow if a 
subject starts prohibited medication or 
procedure was clarified.  
 To clarify the potential reasons 
for permanent discontinu ation  
from study treatment . Section 7.1: Potential r easons for subject 
permanent discontinu ation  from study 
treatment  were updated. 
 To clarify that s ubjects who 
discontinue before Day 1 dosing could be replaced . Section 7.2: It was clarified that s ubjects 
who discontinue after Day 1 dosing will not be replaced . 
 To clarify the potential reasons for discontinuation from study. Section 7.2: Potential reasons for subject 
permanent discontinuation from study were updated 
 To clarify that an indeterminate 
QuantiFERON- TB test result 
obtained at screening can be 
repeated once.  Section 8.3.4: It was clarified that a 
QuantiFERON-TB test can only be 
repeated once if the result is 
indeterminate; tests with positive or 
negative results will not be repeated. 
 To update the process for 
reporting of serious adverse 
events (SAEs), a dverse events of Section 8.4.6; Section 8.4.7.1 (added 
section); and Section 8.4.9: The 
reporting process for SAEs. AESIs, and 
pregnancies was updated. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
9 of 94 Version  Reason for amendment  Main changes to the protocol 
special interest  (AESIs), and 
pregnancies.  
 To incorporate into AESI an 
extended list of events 
characteristic of inhibitors 
targeting other JAK family 
kinases. Section 8.4.7: A dditional AESIs were 
included according to the known adverse 
effects of JAK inhibitors, including 
major cardiovascular even ts, 
thromboembolic events, gastrointestinal perforation, malignancies, infections, and AEs of abnormal liver function tests, 
and renal dysfunction. 
 To clarify the sample size determination. Section 9.1: The sample size was 
calculated using two different methods 
in the original protocol, only the 
appropriate method was kept in this section.  
3.0-Amendment 2/ 
04-Feb-2022 To add clarity and implement minor corrections to text Global: Minor administrative changes to 
the protocol for clarity and to correct 
typographical or minor errors were implemented  
 To further clarify Inclusion Criterion 7 Section  1.1 and Section  5.1 were 
updated. 
 To correct a typo in Inclusion 
Criterion 9 Section 1.1 and Section 5.1 were updated. 
 To clarify the Schedule of Events Section  1.3, Table  1: Week 16 column 
edited to clarify assessments and procedures done only at early 
termination visits that occur before Week 
12.  
 To clarify process/timing of 
eligibility assessment prior to 
randomization  Section 1.3, Table 1: Footnote a was 
modified to reflect the clarification.  
Section  6.3 was updated accordingly. 
 To update the criteria for temporary or permanent discontinuation of study drug in 
case of cytopenia CTCAE Grade â‰¥2. Section  2.2.1, Table  2; Section  7.1; 
Section  8.3.4; and Section  8.4.7 were 
updated. 
 To clarify reporting of adverse 
events and clinically  significant 
laboratory abnormalities  Section 1.3, Table 1, Footnote r; Section  8.3.1; Section  8.3.2 ; 
Section  8.3.3, Section  8.3.4
; 
Section  8.4.4 ; Section  8.4.6 ; 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
Confidential 
10 of 94 Version  Reason for amendment  Main changes to the protocol 
Section  8.4.7  and Section  8.4.9  were 
updated. 
To update the BMI range  
indicated in the inclusion criteria Section  1.1 and Section  5.1: Inclusion 
criterion 10 was updated. 
To update the labor atory tests 
allowed for TB screening  Section 1.1;  Section  1.3, Foootnote c; 
Section  5.2, Exclusion Criterion 17; 
Section  8.3.4, and Section  8.3.4.1  were 
updated. 
To clarify tha t intraarticular and 
intrathecal corticosteroid 
injections are prohibited  Section 1.1; Section 5.1, Exclusion 
Criterion 21; Section  6.4.2 ( Table  4), and 
Section  7.1 were updated. 
To clarify that  non- live-
attenuated boosters for COVID-
19 are allowed  Section 1.1; Section  5.2, Exclusion 
Criterion 24; Sect
ion 6. 4.2, Table 4; and 
Section 7.1 were upda te
d. 
To clarify stati stical  analyses 
and align with the statistical 
analysis plan.  Section 1.1; Section  9.2 and Section  9.3.1 
were updated.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
11 of 94 STATEMENT OF COMPLIANCE  
The study will be conducted in accordance with the protocol, International Council for 
Harmonisation (ICH) Good Clinical Practice (GCP), and applicable local regulations. The 
principal investigator will assure that no planned deviation from, or changes to the protocol will 
take place without prior agreement from the sponsor and documented approval from the 
institutional review board (IRB) /research ethics board (REB), except where necessary to 
eliminate an immediate hazard(s) to the study subjects. All personnel involved in the conduct of 
this study have completed ICH GCP training. 
The protocol, informed consent form(s), recruitment materials, and all subject materials will be 
submitted to the IRB /REB  for review and approval. Approval of both the protocol and the 
consent form must be obtained before any subject is enrolled. Any amendment to the protocol 
will require review and approval by the IRB /REB  before the changes are implemented to the 
study. All changes to the consent form will be IRB /REB  approved. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858-201
Protocol Version 3.0: 04-Feb-2022
Confidential 
12 of 94SIGNATURE PAGE
The signatures below constitute the approval of this protocol a nd provide the necessary 
assurances that this study will be conducted according to this protocol, applicable local 
regulations, and ICH GCP guidelines. 
Name Title Signature and date
(DD-MMM-YYYY)
, MD , Early
Clinical
 Development
Nimbus Lakshmi, Inc.  
 
  
 
 
, BSc , Scien tific and 
Regulatory Affairs 
Innovaderm Research Inc.  
 
 
  
 
, MSc , Biometrics
Innovaderm Research I
nc.  
  
 
 
 
07-Feb-2022,7190436Ä€-6:25782Ä€/,(Ä€$!'$,!'&È€. ",È€$""'È€&."#È€%# #!*%. )+"


	




For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
13 of 94 PRINCIPAL/QUALIFIED INVESTIGATOR SIGNATURE PAGE  
 
Investigator N ame:    
  
Signature:   Date:   
 ` ` (DD- MMM- YYYY)  
Institution Name:    
 
By my signature, I agree to personally supervise the conduct of this study at my study site and 
to ensure its conduct in accordance with the ethical principles that have their origin in the 
Declaration of Helsinki and in compliance with the protocol, infor med consent, i nstitutional 
review board/independent e thics committee procedures, instructions from sponsorâ€™s 
representatives, ICH GCP guidelines, and applicable local regulations governing the conduct 
of clinical studies.  
  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
14 of 94 LIST OF ABBREVIATIONS  
Abbreviation or Specialist Term  Explanation 
AE adverse event  
ADL  activities of daily living  
AESI  adverse event of special interest  
ALT  alanine aminotransferase  
anti-HBc antibody to hepatitis B core antigen  
aPTT activated partial thromboplastin time  
AST  aspartate aminotransferase  
AUC  area under the concentration versus time curve  
AUC % percentage of the area under the concentration versus time curve  
AUC 0-inf area under the plasma concentration versus time curve from time 
0 to infinity  
AUC 0-last area under the plasma concentration versus time curve from time 0 to the time of last measur able concentration 
AUC 0-tau area under the plasma concentration versus time curve from time 0 to the end of the dosing period 
Î²-hCG  Î²-human chorionic gonadotropin  
BMI  body mass index  
BSA body surface area 
BUN  blood urea nitrogen  
Cavg average concentration over the dosing interval  
CLr renal clearance  
Cmax maximum observed concentration  
Cmin minimum observed concentration 
CMH Cochran- Mantel -Haenszel  
COVID -19 Coronavirus Disease 2019  
CPK creatine phosphokinase  
CRO  contract research organization  
CTCAE  Common Terminology Criteria for Adverse Events 
Ctrough trough concentration 
CV coefficient of variation 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
15 of 94 Abbreviation or Specialist Term  Explanation 
CYP 3A cytochrome P450 3A 
DDI drug drug  interaction  
DILI  drug induced liver injury  
DLQI  Dermatology Life Quality Index  
ECG  electrocardiogram  
eCRF  electronic case report form  
EDC  electronic data capture 
EOS  end of study  
EOT  end of treatment  
ET early termination  
F% oral bioavailability  
FDA Food and Drug Administration 
FE%  fraction of the dose excreted in urine 
FIH first in human  
FSH follicle -stimulating hormone  
GCP  Good Clinical Practice  
GGT  gamma -glutamyl- transferase 
hADME  human absorption, distribution, metabolism, and excretion  
HBsAg  hepatitis B surface antigen  
HBV  hepatitis B virus  
HCT  hematocrit  
HCV  hepatitis C virus  
Hgb hemoglobin  
HIV human immunodeficiency virus  
IB Investigator Brochure 
IC30  30% inhibitory concentration 
IC50  half maximal inhibitory concentration 
IC50  90% inhibitory concentration 
ICF informed consent form  
ICH International Council for Harmonis ation  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
16 of 94 Abbreviation or Specialist Term  Explanation 
IL interleukin  
IND Investigational New Drug 
IFNÎ³  interferon gamma 
INR international normalized ratio  
IRB institutional review board  
ITT intent- to-treat  
IV intravenous 
IWRS  Interactive Web Response System  
JAK Janus kinase  
LOCF  last observation carried forward  
LMW  low molecular weight  
MAD multiple ascending  dose  
MCH mean corpuscular hemoglobin  
MCHC  mean corpuscular hemoglobin concentration  
MCV mean corpuscular volume  
MedDRA  Medical Dictionary for Regulatory A ctivities  
mITT  modified intent -to-treat 
MMRM  mixed effect model repeated measures method  
MPV  mean platelet volume  
  
N/A not applicable 
NCI National Cancer Institute  
NMSC  nonmelanoma skin cancer  
NOAEL  no observable adverse effect level 
  
PASI  Psoriasis Area and S everity Index 
PASI -100 100% improvement from baseline in Psoriasis Area and Severity 
Index 
PASI -50 50% improvement from baseline in Psoriasis Area and Severity 
Index 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
17 of 94 Abbreviation or Specialist Term  Explanation 
PASI -75 75% improvement  from baseline  in Psoriasis Area and Severity 
Index 
PASI -90 90% improvement from baseline in Psoriasis Area and Severity 
Index 
PBPK  physiologically based pharmacokinetic 
PCR polymerase chain reaction  
PD pharmacodynamic 
PDE4  phosphodiesterase Type 4 
PGA Physicianâ€™s Global As sessment  
PK pharmacokinetic  
PLT platelet s 
PP per-protocol  
PT prothrombin time  
PUVA  Psoralen  and ultraviolet A 
QC quality control  
QD once daily  
RBC red blood cell (count)  
REB research ethics board  
SAD single ascending dose 
SAE  serious adverse event  
SAP statistical analysis  plan  
SD standard deviation  
SDD spray dried dispersion  
SOC  system organ class  
sPGA static P hysicianâ€™s G lobal A ssessment  
STAT signal transducers and activators of transcription  
t1/2 terminal half-life 
TB tuberculosis  
TBT  T-Spot.TB test  
TEAE treatment -emergent adverse event  
Th T helper  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
18 of 94 Abbreviation or Specialist Term  Explanation 
Tmax time to maximum observed concentration  
TNF  tumor necrosis factor  
TPGS d-Î±-tocopheryl polyethylene glycol 1000 succinate 
TYK2  tyrosine kinase 2  
UV ultraviolet 
WBC white blood cell (count)  
WHO- DD World Health Organization - Drug Dictionary 
WOCBP  women of childbearing potential 
  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
19 of 94 1. PROTOCOL SUMMARY  
1.1. Synopsis  
Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
Title of Study:  
A Phase 2b, Randomized, Multicenter, Double- Blind, Placebo- Controlled, Multiple  -Dose Study to 
Evaluate the Efficacy, Safety, and Tolerability  of NDI -034858 in Subjects with Moderate to Severe 
Plaque Psoriasis  
Phase of Development:  
Phase 2b  
Study Sites :  
Approximately 60 study sites  located in Canada and the United States will participate in this study.  
Number of Subjects (planned):  
Approximately 250 subjects will be randomized in this study (approximately 50 subjects/arm).  
Duration of Study:  
The maximum study duration per subject is approximately 20 weeks, including up to 30 days for the 
screening period, a 12-week treatment period, and a 4 -week  safety follow -up period. 
Investigational Products , Dosage, and Mode of Administration:  
NDI-034858 at  doses of  2 mg, 5 mg, 15 mg, or 30 mg , or placebo will be  orally administered  once 
daily  (QD) for 12 weeks . NDI -034858 will be available in 2 mg, 5 mg , and 15 mg  strength capsules. 
Matching placebo will be identical to  NDI -034858 but will not contain the active ingredient.  
Subjects will be randomized in a 1:1:1:1:1 ratio.  
Objectives:  
The primary objective is: 
â€¢ To assess the efficacy of NDI -034858 orally administered QD at 2 mg, 5 mg, 15 mg, or 
30 mg  for 12 weeks in subjects with moderate to severe plaque psoriasis  
The secondary objectives are: 
â€¢ To assess the safety and tolerability of NDI -034858 orally administered QD at 2 mg, 5 mg, 
15 mg, or 30 mg for 12 weeks in subjects with moderate to severe plaque psoriasis  
â€¢ To evaluate the plasma concentration of NDI -034858 orally administered QD at 2 mg, 
5 mg, 15 mg, or 30 mg in subjects with moderate to severe plaque psoriasis  
The expl oratory objectives are:  
  
 
 
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
20 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
  
 
Endpoints:  
Primary efficacy  endpoint:  
â€¢ Proportion of subject s achieving at least a 75% improvement from baseline in Psoriasis 
Area and Severity Index (PASI -75) at Week 12 
Secondary efficacy  endpoints: 
â€¢ Proportion of subjects achieving a Physician Global Assessment (PGA) of clear (0) or 
almost clear (1) at Week 12 
â€¢ Proportion of subjects achieving at least a 90% improvement from baseline in Psoriasis 
Area and Severity Index (PASI-90) at Week 12 
â€¢ Proportion of subjects achieving a 100% improvement from baseline in Psoriasis Area and Severity Index ( PASI -100) at Week  12 
â€¢ Change from baseline in Dermatology Life Quality Index (DLQI) at Week 12  
Exploratory  endpoints:  
  
 
  
  
  
  
  
  
  
 
  
 
  
  
 
 
  
  
 
Secondary s
afety endpoints:  
â€¢ Incidence of adverse events (AEs) 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
21 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
â€¢ Changes in vital signs, clinical laboratory parameters, and electrocardiograms (ECG s) 
Secondary pharmacokinetic (PK) endpoint: 
â€¢ Measurement of plasma concentrations of NDI -034858 in subjects receiving active 
treatment  
Exploratory  endpoints: 
  
  
Study Design  
This is a Phase 2b, randomized, multicenter, double-blind, placebo- controlled, multiple  dose study 
designed to evaluate the efficacy, safety, and tolerability of NDI-034858 in subjects with moderate to 
severe plaque psoriasis. This study will also evaluate the plasma concentrations of NDI -034858 and 
explore the immune response (in blood and s kin) to NDI034858 in subjects with moderate to severe 
plaque psoriasis.  
Approximately 250 male and female subjects, aged 18 to 70 years (inclusive), with moderate to severe plaque psoriasis will be randomized in this study. To be eligible for the study, the subjects will need to 
have a history of plaque psoriasis for at least 6 months prior to the screening visit. In addition, the 
subjects will  need to have the following characteristics at sc reening and on Day 1:  PASI score â‰¥ 12, 
PGA score  â‰¥ 3, and BSA involved with plaque psoriasis â‰¥ 10% . 
All subjects will read and sign an informed consent form ( ICF) prior to any screening procedures being 
performed. Subjects who fulfill all  inclusion criteri a and none of the exclusion criteria will be included 
into the study. During a screening period of no longer than Day -30 to Day -1, subjects will be 
randomized (on Day -7) to receive either one of the four doses of NDI-034858 (2 mg, 5 mg, 15 mg, or 
30 mg ), or placebo on Day 1. The goal is to have approximately 50 subjects randomized per treatment 
group (1:1:1:1:1 ratio) on Day 1. During the treatment period, NDI-034858 (2 mg, 5 mg, 15 mg, or 30 mg ) or placebo will be  orally administered QD for 12 weeks. Th e 12- week treatment period will be 
followed by a 4- week safety follow -up period.  
For scheduled study visits, subjects will come to the study site on 8 occasions: screening, Day  1, and 
Weeks 1, 2, 4, 8, 12 ( end of treatment [EOT ]), and 16 ( end of study [ EOS] / early termination visit 
[ET]).  
Efficacy will be assessed using PASI, PGA,  
. Quality of life will be evaluated using 
DLQI.  
Safety will be assessed by collecting AEs, recording vital signs, performing physical examinations, and evaluating clinical laboratory and ECGs results.  
Blood sample s will be collected to measure plasma levels of NDI -034858 as follows:  
â€¢ On Day 1 prior to dosing and 1 hour (Â± 5 min) post-dosing; 
â€¢ At Week 4 prior to dosing, 1 hour (Â± 5 min) postdosing, and 4 hours (Â± 10 min) post-
dosing; 
â€¢ At Week 8 prior to dosing; 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
22 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
â€¢ At Week 12 anytime (no study treatment administration at this visit) .  
â€¢ At ET visit anytime (if ET visit is planned before Week 12 visit). 
Urine samples will be collected on Day 1, and at Weeks 4,  12, and 16  
  
 
 
 
 
 
 
 
 
. 
Inclusion/Exclusion Criteria:  
Inclusion criteria:   
In order to be eligible to participate in this study, a subject must meet all following criteria, either at the 
screening and Day 1 visits or only at one of the specified visits (screening or Day 1) as noted in the 
criterion:  
1. Male or female subject aged 18 to 70 year s, inclusive, at the time of consent.  
2. Subject has a history of plaque psoriasis for at least 6 months prior to the screening visit. 
3. Subject had no significant flare in psoriasis  for at least 3 months before screening (information 
obtained from medical chart or subjectâ€™s physician, or directly from the subject).  
4. Subject has moderate to severe plaque psoriasis as defined by a PASI score â‰¥ 12 and a PGA score â‰¥  3 at screening and Day 1.  
5. Subject has plaque psoriasis covering â‰¥ 10% of his or her total BSA at screening and Day 1. 
6. Subject must be a candidate for phototherapy or systemic therapy. 
7. For female subjects of childbearing potential involved in any sexual intercourse that could lead 
to pregnancy: the subject must agree to use a highly effective contraceptive method from at least 4  weeks prior to Day 1 until at least 4 weeks after the last study product administration. 
Highly effective contraceptive methods include hormonal contraceptives (eg, combined oral contraceptive, patch, vaginal ring, injectable, or im plant), intrauterine devices or intrauterine 
systems, vasectomized partner(s) (provided vasectomy was performed â‰¥  4 months prior to 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
23 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
screening), bilateral tubal ligation  or occlusion , or double barrier methods of contraception (eg, 
male condom with cervical cap, male condom with diaphragm, and male condom with 
contraceptive sponge) in conjunction with spermicide.  
Note: Subjects must have been on a stable dose of combined hormonal contraceptives for at least 
4 weeks before Day 1.  
Note: The above list of contraceptive methods does not apply to subjects who are abstinent for at least 4 weeks before Day 1 and will continue to be abstinent from penile- vaginal intercourse 
throughout the study. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study, and the preferred and usual lifestyle of the subject. Periodic abstinence (calendar, symptothermal, postovulation methods) is not acceptable. 
Note:  A female subject of nonchildbearing potential is defined as follows:  
â€“ Female subject who has had surgical sterilization (hysterectomy, bilateral oophorectomy, 
or bilateral salpingectomy);  
â€“ Female subject who has had a cessation of menses for at least 12 months prior to the 
screening visit without an alternative medical cause, and a follicle -stimulating hormone 
(FSH)  test confirming nonchildbearing potential (refer to laboratory reference ranges for 
confirmatory levels). 
8. Female subjects of childbearing potential ha ve had a negative serum pregnancy test at 
screening and negative urine pregnancy test at Day 1. 
9. For male subjects involved in any sexual intercourse that could lead to pregnancy, subject must agree to use one of the highly effective contraceptive methods listed in Inclusion Criterion 7, from Day 1 until at least 12 weeks after the last study product administration. If the female 
partner of a male subject uses any of the hormonal contraceptive methods listed above, this 
contraceptive method should be used by t he female partner from at least 4 weeks before Day  1 
until at least 12 weeks after the last study product administration. 
Note: Male subjects must refrain from donating sperm from Day 1 until at least 12 weeks after 
the last study product administration.  
Note: No restrictions are required for a male subject who underwent a vasectomy at least 
4 months prior to screening and the procedure is documented. If vasectomy procedure is not 
documented or was performed less than 4 months prior to screening, male subje cts must follow 
the same contraception and sperm donation requirements as for nonvasectomized subjects.  
10. Subject has a body mass index ( BMI) within the range of 18 to 42 kg/m2, inclusive 
(BMI  = weight [kg] /[height (m)]2), and total body weight >50 kg (110 lb). 
11. Subject is willing to participate and is capable of giving informed consent. Note: Consent must 
be obtained prior to any study- related procedures.  
12. Subjects must be willing to comply with all study procedures and must be available for the 
duration of the study.  
Exclusion criteria:  
A subject who meets any of the following criteria at the screening and/or Day 1 visits, as applicable, will be excluded from participation in this study:  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
24 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant 
during the study.  
2. Subject has evidence of erythrodermic, pustular, predominantly guttate psoriasis, or -drug 
induced psoriasis.  
3. Subject has a history of skin disease or presence of skin condition that, in the opinion of the investigator, would interfere with the study assessments. 
4. Subject has immune -mediated conditions commonly associated with psoriasis, such as 
psoriatic arthritis, uveitis, inflammatory bowel disease , that require systemic treatment 
(including corticosteroids, immunosuppressants, or biologics).  
Note: Subjects with immune -mediated conditions that do not require systemic treatment may be 
included in the study. Certain therapies such as NSAIDs may be permitted but  should be 
discussed with the Medical Monitor prior to determination of subject eligibility.  
5. Subject has any clinically significant medical condition, evidence of an unstable clinical condition (eg, cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, 
pulmonary, immunologic, or local active infection/infectious illness), psychiatric condition, or 
vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, 
put the subject at undue risk or interfere with interpretation of study results. 
6. Subject had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned 
during the study. 
7. Subject has a history of Class III or IV congestive heart failure as defined by New York Heart Association Criteria.  
8. Subject has been hospitalized in the past 3 months for asthma, has ever required intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or has 
required more than one short -term (â‰¤  2 weeks) course of oral corticosteroids for asthma within 
6 months prior to Day 1.  
9. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated nonmetastatic cutaneous squamous cell or basal cell 
carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded.  
10. Subject has a history of fever, inflammation, or systemic signs of illness suggestive of systemic or invasive infection within 4 weeks prior to Day 1. 
11. Subject has an active bacterial, viral, fungal, mycobacterial infection, or other infection (including TB or atypical mycobacterial disease), or any major episode of infection that 
required hospitalization or treatment with intravenous antibiotics within 12 weeks prior to 
Day 1, or oral antibiotics within 4  weeks prior to Day 1.  
12. Subject has a history of chronic or recurrent infectious disease, including but not limited to 
chronic renal infection, chronic chest infection, recurrent urinary tract infection, fungal infect ion (except for  superficial fungal infection of the nailbed), or infected skin wounds or 
ulcers.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
25 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
13. Subject has a history of an infected joint prosthesis or has received antibiotics for a suspected 
infection of a joint prosthesis if that prosthesis has not be en removed or replaced.  
14. Subject has active herpes infection, including herpes simplex 1 and 2 and herpes zoster 
(demonstrated on physical examination and/or medical history) within 8 weeks prior to Day 1. 
15. Subject has a history of known or suspected congenital or acquired immunodeficiency state or 
condition that would compromise the subjectâ€™s immune status in the opinion of the investigator 
(eg, history of splenectomy, primary immunodeficiency).  
16. Subject has positive results for hepatitis B surface antigens ( HBsAg ), antibodies to hepatitis B 
core antigens ( anti-HBc), hepatitis C virus ( HCV),  or human immunodeficiency virus ( HIV). 
17. Subject has c linical or laboratory evidence of active or latent tuber culosis (TB) infection  at 
screening.  
Note: Subjects with a history of active or latent TB will not be included in the study, unless 
documentation of prior and complete anti-TB treatment, appropriate in duration and type 
according to current local country guidelines , can be provided.  
Note: Subject will be evaluated at screening for latent TB infection with a QuantiFERON -TB 
Gold (QFT) test. Latent TB  is defined as a positive QFT test or two successive indeterminate 
QFT tests at screening . 
Note: The T-Spot.TB test (TBT)  is an acceptable alternative to the QFT test  in regions where 
the TBT is standard practice for tuberculosis screening . The medical monitor should be informed  
prior to using the TBT  in place of the QFT  test. A negative TBT is required  if the QFT test is not 
performed . 
18. Subject with any of the following laboratory values at the screening visit: 
a. Alanine aminotransferase ( ALT ) or aspartate aminotransferase ( AST) values â‰¥ 3 times the 
upper limit of normal ( ULN ); 
b. Hemoglobin < 11.0 g/dL (< 110.0 g/L); 
c. White blood cell count < 3.5 x 109/L (< 3500/mm3); 
d. Absolute neutrophil count of < 1.8 x 109/L (< 1800/mm3); 
e. Absolute lymphocyte count of < 1.0 x 109/L (< 1000/mm3); 
f. Platelet count < 100 x 109/L (< 100,000/mm3); 
g. Total bilirubin Ëƒ 2 times the ULN.  
19. Subjects who have given > 50 ml of blood or plasma within 30 days of screening or > 500 mL 
of blood or plasma within 56 days of screening (during a clinical study or at a blood bank 
donation). 
20. Subject has used any topical medication that could affect psoriasis (including corticosteroids, 
retinoids, vitamin D analogues [such as calcipotriol], JAK inhibitors, or tar) within 2 weeks 
prior to Day 1.  
21. Subject has used any systemic treatment that could affect psoriasis (including oral, intravenous, 
intramusc ular, intraarticular , intrathecal , or intralesional corticosteroids ; oral retinoids ; 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
26 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
immunosuppressive /immunomodulating  medication ; methotrexate ; cyclosporine ; oral JAK 
inhibitors; or apremilast ) within 4 weeks prior to Day 1.  
Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops 
containing corticosteroids are also allowed.  
22. Subject has received any ultraviolet ( UV)-B phototherapy (including tanning beds) or excimer 
laser within 4 weeks prior to Day 1. 
23. Subject has had psoralen and ultraviolet A (PUVA) treatment within 4 weeks prior to Day 1. 
24. Subject has received any  live-attenuated  vaccine within 4 weeks prior to Day 1 or plans to 
receive a live-attenuated vac cine during the study and up to 4 weeks or 5 half -lives of the study 
product , whichever is longer, after the last study product administration.  
Note: Non-live-attenuated vaccines or boosters for Coronavirus Disease 2019 ( COVID -19) (eg, 
RNA- based vaccines, inactivated adenovirus-based vaccines, protein- based vaccines) are 
allowed during the study. The study site should follow local guidelines related to COVID-19. 
25. Subject is currently receiving a nonbiological investigational product or device or ha s received 
one within 4 weeks prior to Day 1. 
26. Subject has received any marketed or investigational biological agent within 12 weeks or 
5 -half- lives  (whichever is longer) prior to Day 1 (except those listed in Exclusion Criterion 27 
and 28 that are to be excluded for 6 months). 
27. Subject was previously enrolled in any study with NDI-034858. 
28. Subject has a history of lack of response to any therapeutic agent targeting interleukin ( IL)-12, 
IL-17, and/or IL-23 (eg, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, 
tildrakizumab, risankizumab) at approved doses after at least 12 weeks of therapy, and/or 
received one of these therapies within 6 months prior to Day 1. 
29. Subject has received rituximab or other immune cell  depleting therapy within 6 months. 
30. Subject is currently being treated with strong or moderate cytochrome P450 3A (CYP3A4) 
inhibitors (such as itraconazole)  or has received moderate or strong CYP3A4 inhibitors within 
4 weeks prior to Day 1. 
31. Subject is currently being treated with terbinafine or has received terbinafine within 4 weeks 
prior to Day 1. 
32. Subject has consumed grapefruit within 1 week prior to Day  1. 
Note: Consumption of grapefruit must be avoided during the treatment period  and for at least 
1 week after last dose adminis tration . 
33. Subject has used tanning booths within 4 weeks prior to Day 1, has had excessive sun 
exposure, or is not willing to minimize natural and artificial sunlight exposure during the study.  
Note: Use of sunscreen products and protective apparel are recommended when sun exposure 
cannot be avoided.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
27 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
34. Subject has a known or suspected allergy to NDI -034858 or any component of the 
investigational product, or any other significant drug allergy (such as anaphylaxis or 
hepatotoxicity). 
35. Subject has a known history of clinically significant drug or alcohol abuse in the last year prior 
to Day 1. 
36. For subjects consenting to biopsy collection only:  
â€“ Subject has a history of an allergic reaction or significant sensitivity to lidocaine or other local anesthetics.  
â€“ Subject has a history of hypertrophic scarring or keloid formation in scars or suture sites. 
â€“ Subject has taken anticoagulant medication, such as heparin, low molecular weight (LMW ) 
heparin, warfarin, or antiplatelet agents (except low-dose aspirin â‰¤ 81 mg which will be 
allowed), within 2 weeks prior to Day 1, or has a contraindication to skin biopsies . 
Nonsteroidal -anti-inflammatory  drugs will not be considered antiplatelet  agents and will be 
allowed. 
Statistical methods:   
Categorical variables will be presented in tables as frequencies and percentages. Continuous variables 
will be summarized in tables and will include the number of subjects, mean, standard deviation (SD), median, minimum, and maximum.  
Further details regarding the efficacy and safety variable definitions, analyses strategy, statistical 
justification, and techniques for handling missing values (if applicable) will be detailed in a separate 
statistical analysis plan (SAP)  that will be prepared before the database is locked and any analyses are 
undertaken. Any deviation(s) from the SAP will be described and justified in the final Clinical Study 
Report, as appropriate.  
All statistical tests will be two -sided and will be performed with a significant level of 0.05, unless 
otherwise specified in the SAP. To account for the multiplicity testing in the primary endpoint analysis, 
each active treatment group will be compared to the placebo group using a hierarchical testing 
procedure, starting with the highest dose group and en ding with the lowest dose group (30-mg 
NDI-034858, 15- mg NDI -034858, 5- mg NDI -034858, and 2- mg NDI -034858, in order). No 
adjustment to alpha will be made to account for multiple testing between treatment groups for the 
secondary  efficacy en dpoints.  
Efficacy Analyses:   
The primary endpoint can be translated as a responder analysis, where a subject will be classified as 
responder if he or she achieves PASI -75 at Week 12. The comparison between groups for the primary 
endpoint will be done using a Cochran- Mantel -Haenszel (C MH) , with prior treatment with biologics  
included as a stratification factor . The primary efficacy analysis will be performed on the modified 
intent- to-treat ( mITT) analysis set, while the per-protocol (PP) analysis set will be used as a sensitivity 
analysis.   
The secondary endpoints involving proportions of subjects will be analyzed using the same approach (CMH test) as described for the primary efficacy analysis, at each time point and  based on the mITT 
analysis. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
28 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
The continuous secondary endpoints involving absolute change from baseline will be analyzed using a 
mixed effect model repeated measures method (MMRM) based on the mITT analysis set only . The 
model will include treatment, visit, treatment by- visit interaction, and prior treatment with biologics as 
fixed effects, and baseline score as a covariate.  
Safety Analyses:   
All safety analyses will be conducted using the safety analysis set . No inferential statistics will be 
performed on safety variables. 
Adverse events and serious adverse events (SAEs) will be presented and tabulated according to the 
Medical Dictionary for Regulatory Activities (MedDRA) classification  by treatment group. 
Descriptions of AEs will include the start date, the stop date (if it resolved), th e severity and 
seriousness of the AE, the causality of the AE to study product, action taken with respect to the study 
product, and the outcome.  Reported AEs will be summarized by the number of subjects reporting the events, as well as by system 
organ cla ss, preferred term, reported verbatim severity, seriousness, and investigatorâ€™s assessment of 
the relationship to study product. For the summary of AEs by severity, each subject will be counted 
only once within a system organ class or a preferred term by using the AEs with the highest intensity 
within each category for each analysis. For the summary of AEs by relationship to study product, each 
subject will be counted only once within a system organ class or a preferred term by using the AEs 
with the greate st reported relationship within each category. For the summary of AEs by relationship to 
study product and severity, each subject will be counted only once within a system organ class or a 
preferred term by using (1)  the greatest reported relationship followed by (2) the highest reported 
intensity.  
All information pertaining to AEs noted during the study will be listed by treatment group, subject, 
detailing verbatim, system organ class, preferred term , start date, sto p date, intensity, outcome, action 
taken with respect to study product, and relationship to study product. The AE onset will also be shown relative (in number of days) to the day of study product administration. Serious adverse events will be 
tabulated by treatment group, relationship to the test article, and a reference to the occurrence of the SAEs to the relative day of dosing. Similar listings will be provided for the SAEs and AEs leading to 
the discontinuation from the study. 
Results from vital signs, laboratory analyses, and ECGs will be tabulated by treatment group and visit 
using descriptive statistics. The observed value at each visit , as well as the change from baseline will 
be presented. Shift tables describing shifts to out-of- normal range will b e provided for clinical 
laboratory results, and normal to a bnormal shift tables may be provided for vital signs.  
Concomitant medications will be coded with the World Health Organization â€“ Drug Dictionary 
(WHO- DD) and listed by subject. Summary of medications will also be tabulated.  
Pharmacokinetic Analyses : 
Concentration data will be listed per subject and summarized descriptively per dose.  
 
. 
Other Analyses:  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
29 of 94 Name of Sponsor/Company:  
Nimbus Lakshmi , Inc.  Name of Investigational Product:  
NDI-034858 Name of Active Ingredient:  
NDI-034858 
Descriptive summaries of subject disposition and baseline characteristics (including demographic data 
and prior concomitant therapy) will be presented by treatment group. In addition, a list of subjects who 
discontinued from the study along with discontinuation reason will be provided.  
Protocol deviations will be summarized by treatment and category.  
Sample Size Consideration:  
The sample size determination is based on testing equality of two independent response rates using a 
2-sided test with significance level of alpha = 0.05 and power 85%. The formula used for the 
calculation is the same as used in the nQueryÂ® (ie, normal approximation with Fleissâ€™ formula and 
continuity correction).  
Assuming the placebo response rate at end of Week 12 is 10% (proportion of subjects achieving 
PASI -75), at least one of the NDI -034858 dose treatment groups will have a response rate at least 40%, 
and after adjustment of 15% dropout rate, a total of 250 subjects (50 per treatment group) will be 
randomized in the study.  
Fifty subjects per treatment group, with 1-sided, 2- sample Fisherâ€™s exact test at significant level 0.05, 
will provide at least approximately 90% power to detect at least 30% difference in the response rate in 
PASI -75 between any two treatment groups. 
  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201
Protocol Version 3.0: 04-Feb-2022
Confidential
30of 941.2. Study Diagram
Figure 1: Study Diagram
Abbreviation: QD, once daily.
1.3. Schedule of Events
The screening evaluation will only be performed after the subject has agreed to participate and 
has signed and dated the ICF. No treatment or study- related procedures will be initiated before 
the informed consent is signed. The Day 1 visit must be performed, at the latest, 30 days after the screening visit.
The s creening evaluation will be performed according to the inclusion and exclusion criteria. If 
the subject fulfills all inclusion criteria and no exclusion criteria, he or she may be included in 
the st udy.
Table 1provides a description of the procedures to be performed at each visit.
Unless specified otherwise, the study assessments scheduled during the treatment period must be 
performed before study product administration , if applicable (no drug administration the day of 
Week 12 visit).
,7190 436Ä€ - 6:25782Ä€ /,( Ä€ $!'$,!'&È€.  ",È€$""'È€&. "#È€%# #!* %. ) +"
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
31 of 94 Quality of life assessment (DLQI) ,  
 must be completed prior to other efficacy assessments (PASI, PGA,  
). 
The COVID -19 pandemic may impact the ability to adhere to the study procedures de scribed in 
Table 1 due to challenges that include, but are not limited to, subject  preferences, site closures, 
travel restrictions, and quarantines. Please refer t o Section  4.2 for more details on allowable, as 
necessary, modifications to the protocol due to COVID-19 restrictions. 
Every attempt should be made to adhere to the visit schedule. If an unscheduled visit (eg, an 
additional visit not specified in Table 1) is unavoidable or necessary, the investigator  may allow 
it at his or her discretion. All study -specific unscheduled visits should be documented in the 
subjects record and the appropriate clinical data should be entered into the Electronic Data 
Capture (EDC) .
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI7DEOH6FKH GXOHRI(YHQWV
6WXG\9LVLWV 6FUHHQLQJ3HULRG 7UHDWPHQW3HULRG)ROORZXS
RU(DUO\
7HUPLQDWLRQ
6FUHHQLQJ
9LVLW'D\
D'D\:HHN :HHN :HHN :HHN:HHN
(QGRI
7UHDWPHQW:HHN
:LQGRZVGD\V WR Â“ Â“ Â“ Â“ Â“ Â“ Â“
,QIRUPHGFRQVHQW ;
'HPRJUDSKLFV ;
0HGLFDODQGVXUJLFDOKLVWRU\ ; ;
,QFOXVLRQDQGH[FOXVLRQFULWHULD ;D;
3UHJQDQF\WHVWE; ; ;;;;; ;
6HURORJ\+,9+%9>+EV$JDQWL+%F@+&9 ;
4XDQWL)(5217%*ROG WHVWF;
9LWDOVLJQVG; ; ;;;;; ;
&RPSOHWHSK\VLFDOH[DPLQDWLRQ ; ;
7DUJHWHGSK\VLFDOH[DPLQDWLRQ ; ; ; ;
&OLQLFDOODERUDWRU\ WHVWVKHPDWRORJ\
FKHPLVWU\XULQDO\VLV)6+H; ; ; ; ; ; ; ;
)DVWLQJOLSLGSDQHO ; ;
(OHFWURFDUGLRJUDPJ; ; ;;;;;
3$6, ; ; ; ; ; ; ;K
3 * $ ; ; ;;;; ;K
'/4,4XHVWLRQQDLUH ; ; ; ; ;K
5DQGRPL]DWLRQ ;
2QVLWHVWXG\SURGXFWDGPLQLVWUDWLRQL; ;;;;
'LVSHQVHRIVWXG\SURGXFW ; ; ; ; ;
&ROOHFWLRQRIVWXG\SURGXFW ; ; ; ; ; ;K
6XEMHFWGRVLQJGLDU\GLVWULEXWLRQFROOHFWLRQ
UHYLHZ; ; ; ; ; ; ;K
%ORRGVDPSOHVIRU1',FRQFHQWUDWLRQ ;M;N;O;P;K'RFX6LJQ(QYHORSH,'')')%)$&
PPD
)RUQRQFRFRQQQQQRQ
;;UQQQQ
)RRPPHUFLDOXVHRQO\\O\\\\
;;RQHRVVVVHXV;;OXXXX
LDUUUUFHU
;;PHHH
RH
)RFRP
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI6WXG\9LVLWV 6FUHHQLQJ3HULRG 7UHDWPHQW3HULRG)ROORZXS
RU(DUO\
7HUPLQDWLRQ
6FUHHQLQJ
9LVLW'D\
D'D\:HHN :HHN :HHN :HHN:HHN
(QGRI
7UHDWPHQW:HHN
:LQGRZVGD\V WR Â“ Â“ Â“ Â“ Â“ Â“ Â“
0HGLFDOSKRWRJUDSKVRSWLRQDOT;; ;
&RQFRPLWDQWPHGLFDWLRQ ; ; ; ; ; ; ; ;
$GYHUVHHYHQWVHYDOXDWLRQ ;U;;;;; ;
$EEUHYLDWLRQVDQWL+%FDQWLERG\ WRKHSDWLWLV%FRUHDQWLJHQ %6$ERG\VXUIDFHDUHD'/4,'HUPDWRORJ\/LIH4XDOLW\,QGH[ )6+ )ROOLFOH6WLPXODWLQJ+RUPRQH
+EV$JKHSDWLWLV%VXUIDFHDQWLJHQ+%9KHSDWLWLV%YLUXV+&9 KHSDWLWLV&YLUXV+,9KXPDQLPP XQRGHILFLHQF\YLUXV 3$6,3V RULDVLV
$UHDDQG6HYHULW\,QGH[3*$ 3K\VLFLDQÂ¶V*OREDO$VVHVVPHQW4' RQFHGDLO\
D'D\LVQRWDVXEMHFWYLVLWDQGLVRQO\SODQQHGIRUUDQGRPL]D WLRQ%HIRUH'D\DYDLODEOHHOLJLELOLW\LQIRUPDWLRQZLOOEH UHYLHZHGDQG6XEMHFW(OLJLELOLW\)RUPZLOO
EHVXEPLWWHGIRUDSSURYDO6XEMHFW ZLOOWKHQEHUDQGRPL]HG
E)RUIHPDOHVXEMHFWVRIFKLOGEHDU LQJSRWHQWLDORQO\VHUXPSUHJQ DQF\WHVWDWVFUHHQLQJDQG XULQHSUHJQDQF\WHVWDWWKHRWKHUYL VLWV
F$76SRW7%WHVWPD\EHXVHGDVDQDOWHUQDWLYHWRWKH4XDQWL)(521 7%*ROGWHVW DVSHU([FOXVLRQ&ULWHULRQ
G,QFOXGLQJKHLJKWDQGZHLJKW+HLJKWZLOOEHPHDVXUHGRQO\DWVF UHHQLQJ
H)6+WREHSHUIRUPHGDWVFUHHQLQJRQO\IRUIHPDOHVZKRKDVKDG DFHVVDWLRQRIPHQVHVIRUÂ•PRQWKVSULRUWRWKHVFUHHQLQJYLV LWZLWKRXWDQDOWHUQDWLYHPHGLFDO
FDXVH
J,QDGGLWLRQWRWKHWLPHSRLQWVVSHFLILHGLQWKHVFKHGXOHRIHYH QWV(&*VPD\EHSHUIRUPHGDWDQ\WLPHGXULQJWKHVWXG\LILQW KHRSLQLRQRIWKHLQYHVWLJDWRULWLV
FOLQLFDOO\ZDUUDQWHG
K2QO\SHUIRUPHGDW(7YLVLWLI(7 YLVLWLVSODQQHGEHIRUH:HHN  YLVLW
L6WXG\SURGXFWVZLOOEHWDNHQDWKRPH4'IRUZHHNVH[FHSWRQ YLVLWGD\VZKHQWKHVWXG\SUR GXFWVZLOOEHDGPLQ LVWHUHGRQVL WH1RGUXJDGPLQLVWUDWLRQWKHGD\RI
:HHNYLVLW
M6DPSOHVWREHWDNHQSUHGRVHDQGKRXU rPLQSRVWGRVHRQ'D\
N6DPSOHVWREHWDNHQSUHGRVHKRXU rPLQSRVWGRVHDQGKRXUV r PLQSRVWGRVHDW:HHN
O6DPSOHVWREHWDNHQSUHGRVHDW:HHN
P6DPSOHVWREHWDNHQDQ\WLPHDW:HHNQRVWXG\WUHDWPHQWDGPL QLVWUDWLRQDWWKLVYLVLW'RFX6LJQ(QYHORSH,'')')%)$&
PPDP
PD
)RUQRQ(&*VPD\&*VP
HNHNYLVLY
WRQWRFRPPHUFLDOXVHRQDWRORJ\/LRORJ\/
LPPXQRGHPPXQR
HHOLJLELOLWHHOLJLE
DQGDQGXULQHXULQ
DVSHU([DVSHU(
RIPHQVHVIPHQVRQO\;\\;;QO\\\\
RQ
RQF
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
Confidential 
34 of 94 Study Visits  Screening Period  Treatment Period  Follow -up 
or Early 
Termination  
 Screening  
Visit  Day 
-7a Day 1  Week 1  Week 2  Week 4  Week 8  Week 
12/End of 
Treatment  Week 16  
Windows (days)  -30 to -8 (Â±1)  (Â±2) (Â±2) (Â±2) (Â±3) (Â±3) (Â±4) 
 
.  
q At certain  study sites, i n a subset  of subjects  who consent , optional medical photographs of full body , front and back, will be taken . 
r Adverse events evaluation begins after dosing on Day 1.  
Note: Unscheduled visits are described in Section  1.3. 
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
35 of 94 2. INTRODUCTION 
2.1. Background  
2.1.1. Plaque Psoriasis 
Plaque psoriasis is a chronic inflammatory skin disorder characterized by thickened and inflamed 
areas of skin. These plaque regions exhibit a confluent parakeratotic scale, loss of the granular cell layer, increased number of epidermal cell layers, and prominent lymphocyte infiltration.
1 
Markers of inflammation and specific immune cell subsets are highly elevated in psoriatic plaques. This includes elevated mRNA and protein levels of IL-23 / T helper (Th) 17 activity (such as IL -23, IL -17A, IL -17F, and IL-22), elevated markers of keratinocyte activation and 
proliferation, and markers of infiltrating immune cells.
2  
Plaque psoriasis is a prevalent disease worldwide, with 1 -2% of people affected, and its severity 
is generally categorized based on PASI, total BSA affected, and PGA.3,4 The primary goal of 
psoriasis therapies is clearance of psoriatic plaques, and the benchmark level of treatment response in most current clinical studies is PASI -75 at Week 12 or 16. This benchmark is readily 
achieved by the majority of patients treated with biologic therapies targeting tumor necrosis factor (TNF) -Î±, IL -12/23, IL-23, and IL-17.
5 
While there are multiple biologic agents approved for the treatment of moderate to severe plaque psoriasis, there are a very limited number of oral small molecule therapies available to patients. 
Some patients can be treated with oral immunosuppressive dru gs; however these treatments 
generally exhibit limited efficacy.
6 The only other approved oral agent for the treatment of 
plaque psoriasis is a phosphodiesterase Type 4 (PDE4) inhibitor (apremilast), which is generally safe but exhibits significantly lower efficac y than most biologic therapies and has recognized 
tolerability liabilities including severe diarrhea, nausea, and vomiting in some patients.
5,7,8 
2.1.2. NDI-034858 
NDI-034858 is a small molecule allosteric inhibitor that binds to the JH2 pseudokinase domain 
of tyrosine kinase 2 (TYK2), leading to inhibition of the TYK2 catalytic JH1 kinase domain and 
subsequent downstream signaling events. The allosteric interaction of NDI-034858 with the TYK2 JH2 domain results in highly selective inhibition of TYK2 kinase activity compared to the 
other homologous proteins in the Janus kinase (JAK) family of nonreceptor tyrosine kinases 
(JAK1, JAK2, and JAK3).  
Tyrosine kinase 2 ( TYK2 ) catalyzes the phosphorylation of signal transducers and activators of 
transcription (STAT) proteins downstream of several cytokine receptors, including the IL-23 
receptor, as well as the Type I interferon receptor and the IL -12 receptor.
9 The activation of 
TYK2  dependent receptors by their cytokine ligands results in the activation of 
STAT ---dependent transcription and cellular functional responses specific for the receptors and 
cell types they are expressed on.10 The cytokine signaling pathways regulated by TYK2 play key 
roles in several immune -mediated disorders. Most relevant for psoriasis pathogenesis, the 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RIF\WRNLQH,/LVFHQWUDOIRUWK HH[SDQVLRQDQGVXUYLYDORI7K FHOOVDQGLQQDWHO\PSKRLGFHOOV
ERWKRIZKLFKKDYHEHHQVKRZQWRSO D\NH\SDWKRJHQLFUROHVLQD XWRLPPXQLW\,/
VWLPXODWLRQGULYHVWKHSURGXFWL RQRINH\SURLQIOD PPDWRU\F\WRNL QHVE\7KFHOOVLQFOXGLQJ
,/$,/)DQG,/DOORI ZKLFKDUHHIIHFWRUPROHFXOHV LQSVRULDWLFVNLQ
 6WXG\5DWLRQDOH
7KHUHDUHFXUUHQWO\DYHU\OLPL WHGQXPEHURIVPDOORUDOPROHFXO HWKHUDSLHVDYDLODEOHWRSDWLHQWV
ZLWKSODTXHSVRULDVLV $VDIHZHOOWROHUD WHGDQGKLJKO\ HIILFD FLRXVRUDOWKHUDS\IRUSODTXH
SVRULDVLVZRXOGSURYLGHDQDSSHD OLQJWUHDWPHQWRSWLRQIRUERWK SDWLHQWVDQGSK\VLFLDQV
1',KDVWKHSRWHQWLDOWRDGGYD OXHWRWKHWUHDWPHQWDOJR ULWKPRISVRULDVL VSDUWLFXODUO\
FRQVLGHULQJWKHODFNRIKLJKO\H IILFDFLRXVRUDODJHQWV,QKLELW LRQRI7<.E\1',LV
H[SHFWHGWRLPSDFWSVRULDVLVSD WKRJHQHVLVSULPDULO\WKURXJKLWV HIIHFWVRQWKH,/7K7K
D[LV,QDGGLWLRQVDIHW\DQGHIIL FDF\GDWDLQSVRULDVLVSUHVHQ WHGWRGDWHIRUD7<.LQKLELWRU
%06RUGHXFUDYDFLWLQLEZKLFKDOVRLQKLELWV7<. DFWLYLW\WKURXJKDOORVWHULF
ELQGLQJRIWKH-+GRPDLQVHWVWKH FOLQLFDOSUHFHGHQFHIRUVHO HFWLYHO\WDUJHWLQJ7<.DFWLYLW\LQ
WKLVGLVHDVH6SHFLILFLQKLE LWLRQRI7<.LVH[SHFWHGWREHPRU HHIILFDFLRXVWKDQDQ\FXUUHQWRUDO
WKHUDSLHVDQGFRXOGEH FRPSDUDEOHWRWKHHIILFDF\REVHUYHGIRU VRPHELRORJLFWKHUDSLHVFXUUHQWO\
LQXVH
 &OLQLFDO([SHULHQFH 6WXG\
6WXG\ZDVDUDQGRPL]HGVLQJOHFHQWHUGRXEOHEOLQGS ODFHERFRQWUROOHGVLQJOHDQG
PXOWLSOHDVFHQGLQJGRVHVWXG\L QKHDOWK\VXEMHFWVWR\HDU VRIDJH7KLVVWXG\LQYHVWLJDWHG
VLQJOHDVFHQGLQJGRVHV 6$'RIPJPJPJPJDQG PJDQGPXOWLSOH
DVFHQGLQJGRVHV0$'RIP JDQGPJJLYHQ4'IRUGD\V $QDGGLWLRQDO RSHQODEHO
FRKRUWZDVDOVRLQFOXGH GWRHYDOXDWHWKHFR PSDUDWLYHELRDYDLODE LOLW\
WRDVVHVVWKH3. RIVLQJOHRUDO
GRVHV RI1',LQKHDOWK\V XEMHFWV XQGHUIHGDQGIDVWHG
FRQGLWLRQV 
 6DIHW\5HVXOWVLQ6WXG\
,Q6WXG\SDUWLFLSDQWVKHDOWK\YROXQWHHUVZHUHHQ UROOHGLQVLQJOHGRVHFRKRUWV
 WUHDWHGZLWK1',UDQJLQJIURPPJWRPJDQG WUHDWHGZLWKSODFHER
7UHDWPHQWZLWK1',ZDVJHQH UDOO\VDIHDQGZHOOWROHUDWHG $WRWDORIRI
SDUWLFLSDQWVWUHDWHGZLWK1', H[SHULHQFHGDWOHDVWRQH7 ($(FRPSDUHGZLWKRI
WUHDWHGZLWKSODFHER7KHP RVWFRPPRQ$HVDVVRFLDWHGZ LWK1',WUHDWPHQW
ZHUHDFQHLIRUPGHUPDWLWLVSDSXO DUUDVKDQGDSKWKRXVVWRPDWLWLV WKHVHHYHQWV ZHUHPLOGDQGGLG
QRWOHDGWRWUHDWPHQWGLVFRQWL QXDWLRQ7KHUHZHUHQRGHDWKVVH ULRXVRUVHYHUH$(VRU$(V
OHDGLQJWRGLVFRQWLQXDWLRQIUR PVWXG\RUVWXG\GUXJLQHLWKHUD FWLYHRUSODFHERWUHDWHG
SDUWLFLSDQWV1RDGYHU VHWUHQGVZHUHQRWHGL QVDIHW\ODERUDWRU\ WHVWV(&*VYLWDOVLJQVRU
SK\VLFDOH[DPILQGLQJV'RFX6LJQ(QYHORSH,'')')%)$&
PPD
PPD
PPDU QRQFRPPHUFLDOXVHRQO\WLYHOWLYH
RUHHIILFUHHIILF
GIRUVRPIRUVR
HFHQWHUFHQWH
WK\\VXEMHVXE
PJPJ
PJDQGJDQG
YDOXDWHWYDOXDW)R
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI,Q6WXG\ SDUWLFLSDQWVKHDOWK\YROXQWHHU VZHUHHQUROOHGLQPXOWLSOH GRVHFRKRUWV
WUHDWHGZLWKHLWKHUP JRUPJRI1',GDLO\IRU WZRZHHNVDQGWUHDWHGZLWK
SODFHERGDLO\IRUWZRZHHNV7 UHDWPHQWZLWK1',ZDVJHQ HUDOO\VDIHDQGZHOOWROHUDWHG
$WRWDORIRI SDUWLFLSDQWVWUHDWHGZLWK1',á€© KDGDWOHDVWRQH7($(GXULQJ
WKHVWXG\SHULRGFRPSDUHGZLWKRIZKRUHFHLYHGSODFH ER7KHPRVWFRPPRQ
Â•VXEMHFWV7($(VREVHUYHGE\SUHI HUUHGWHUPZHUHDFQHLIRUP GHUPDWLWLVUHSRUWHGLQ
VXEMHFWVWUHDWHGZLWK1', DOOZKRUHFHLYHGPJDQ GLQZKRUHFHLYHGPJ
GDLO\IRUZHHNV3DSXODUUDV KZDVUHSRUWHGLQVXEMHFWVWUH DWHGZLWKPJ1',$OO
HYHQWVRIDFQHLIRUPGHUPDWLWLVRUSDSXODUUDVKZHUHGHHPHGWR EHGUXJ UHODWHG7KH\ZHUHDOO
PLOGLQLQWHQVLW\DQGUHVROYHGZ LWKLQRQHWRWZRZHHNVRIRQVHW ZLWKRXWUHTXLULQJWUHDWPHQW
GLVFRQWLQXDWLRQ$SKWKRXVXOFHURF FXUUHGLQVXEMHFWVLQWKH PJJURXSDQGLQWKHPJ
JURXSDOORIZKRPDOVRH [SHULHQFHGDFQHLIRUPGHUPDWLWLV$OOH YHQWVZHUHFRQVLGHUHG
GUXJUHODWHG1RQHRIWKHVHHYHQ WVZHUHREVHUYHGLQWKHSODFHE RJURXS7KHUHZHUHQRGHDWKV
VHULRXVRUVHYHUH$(VRU$(V OHDGLQJWRGLVFRQWLQXDWLRQIURPW KHVWXG\2QHSDUWLF LSDQWLQWKH
PJJURXSGLVFRQWLQXHGW UHDWPHQWGXHWRDWU LDOILEULOODWLRQD VVRFLDWHGZLWKK\SHUWK\URLGLVPEXW
FRPSOHWHGVWXG\IROORZXS7KLVHY HQWZDVGHHPHGXQUHODWHGWRV WXG\GUXJDQGZDVQRWVHULRXV
1RDGYHUVHWUHQGVZHUHQRWHGLQV DIHW\ODERUDWRU\WHVWV(&*V YLWDOVLJQVRUSK\VLFDOH[DP
ILQGLQJV
2IVXEMHFWVHQUROOHGLQWKHRSH QODEHOFRKRUWRQO\7($(RI RUDOKHUSHVZDVREVHUYHGLQ
VXEMHFWDIWHUUHFHLYLQJD VLQJOHGRVHRIPJ1', 6''IRUPXODWLRQXQGHU
IDVWLQJFRQGLWLRQV7KLV7($(ZD VPLOGLQVHYHULW\DQGZDVMXGJ HGDVXQUHODWHGWR1',
E\WKHLQYHVWLJDWRU7KLVHYHQWZD VDOVRD7($(RIVSHFLDOLQWH UHVWDQGZDVUHVROYHGEHIRUHWKH
HQGRIVWXG\1R6$(VZHUHREVHU YHGDQGQRQHRIWKHVXEMHFWVH[ SHULHQFHG7($(VOHDGLQJWR
GRVHGLVFRQWLQXDWLRQGXU LQJWKHVWXG\SHULRG
 3KDUPDFRNLQHWLF5HVXOWVLQ6WXG\
,QWKHVWXG\WKHDEVRUSWLRQRI1 ',ZDVJHQHUDOO\UDSLG ZLWKWKHPHDQSHDNSODVPD
FRQFHQWUDWLRQVREVHUYHGDWDP HGLDQWLPHWRPD[LPXPREVHUYHGFR QFHQWUDWLRQ7 PD[RI
KRXUVSRVWGRVHLQWKH6$'& RKRUWVDQGWKH0$'&RKRUWV DQG
)RU&RKRUWVGRVHVRI DQGPJ1',WKHPHD QPD[LPXPREVHUYHG
FRQFHQWUDWLRQ& PD[LQFUHDVHGLQDQDSSUR[LPDWH O\GRVHSURSRUWLRQDOPDQQHU
)RU
GRVHVRIDQGPJ&RKRU WVDQGUHVSHFWLYHO\ WKHPHDQ& PD[LQFUHDVHGLQD
OHVVWKDQGRVHSU RSRUWLRQDOPDQQHU'RFX6LJQ(QYHORSH,'')')%)$&
PPD
PPD
PPD)RUQRQFRPPHUFLDOXVHRQO\RVWXG\VWXG
*VYLWDOYLWDO
7($(7($(
PJ1PJ1
HULW\DQGLW\DQ
$(RIVS$(RI
GQRQHRQRQH
SHULRGULRG
XOWOWVVLQLQ6
I1',I1',
PHGLDPHG
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI6LPLODUO\IRU&RKRUWV GRVHVRIDQGPJ1', WKHPHDQDUHDXQGHUWKH
SODVPDFRQFHQWUDWLRQYHUVXVWLPH FXUYHIURPWLPHWRLQILQLW\ $8&LQILQFUHDVHGLQDQ
DSSUR[LPDWHO\GRVHSU RSRUWLRQDOPDQQHU
8SRQPXOWLSOHGRVHDGPLQLVWUD WLRQIRUGD\VDWDRUPJ GDLO\GRVH&RKRUWVDQG
UHVSHFWLYHO\WKHDFF XPXODWLRQUDWLRIRU& PD[ZDVDQGUHVSHFWLYHO\ DQGWKHDUHDXQGHUWKH
SODVPDFRQFHQWUDWLRQYHUVXV WLPHFXUYHIURP WLPHWRWKHHQGR IWKHGRVLQJSHULRG$8& WDX
ZDVDQGUHVSHFWLYHO\
WKHWHUPLQDOKDOIOLIH
WZDVFRQVLVWHQWDFURVVWKHGRV HOHYHOVWHVWHGDQGUDQJHGIURP 
 3KDUPDFRG\QDPLF5HVXOWVLQ6WXG\
7KH3'HIIHFWRIWUHDWPHQW ZLWK1',LQ6WXG\ZD VDVVHVVHGXVLQJDQH[YLYR
LPPXQHDVVD\PHDVXULQJWKHDPRXQWRI 7<.GHSHQGHQWLQWHUIHURQ JDPPD,)1È–SURGXFHGE\
ZKROHEORRGVDPSOHVWKDWZHUHV WLPXODWHGZLWKWKHF\WRNLQHV,/ DQG,/DWEDVHOLQH
SUHGRVHDQGIROORZLQJWUHDWPHQW ,QFUHDVLQJH[SRVXUHVWR1', OHGWRJUHDWHUUHGXFWLRQ
LQ,)1È–FRQILUPLQJDUREXVW HIIHFWRIWKLVFRPSRXQGRQELRORJL FDOHQGSRLQWVUHOHYDQWWRWKH
SDWKRJHQHVLVRIVHYHUDO DXWRLPPXQHGLVHDVHV'RFX6LJQ(QYHORSH,'')')%)$&
PPD
PPD
PPD
PPD
PPDPPDPPD
VHRQO\HGIURPGIURP
O XVH
FLDOXHUFLDPHUPPFRPQFRQRQ
RUQR)RU)RQO\QP
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI 6WXG\
6WXG\ZDVD3KDVH UDQGRPL]HGPX OWLFHQWHUGRXEOHE OLQGSODFHERFRQWUROOHG
PXOWLSOHDVFHQGLQJGRVHVWXG\RI1',LQVXEMHFWVZLWKPRG HUDWHWRVHYHUHSODTXH
SVRULDVLV7KHVWXG\REMHFWLYH ZDVWRSURYLGHSUHOLPLQDU\HYLGH QFHRIVDIHW\WROHUDELOLW\
SKDUPDFRNLQHWLFVSKDU PDFRG\QDPLFVDQGHDUO\HIILFDF\LQDPRG HUDWHWRVHYHUHSODTXH
SVRULDVLVSRSXODWLRQ
7KHVWXG\HQUROOHGDWRWDORIV XEMHFWVZKRZHUHUDQGRPL]HG WRGDLO\WUHDWPHQWZLWKHLWKHU
SODFHER1 RURIGRVHVRI1 ',1 IRUDWRWDO GXUDWLRQRIGD\V'RVHOHYHOV
ZHUHPJ PJ RUPJ

 (IILFDF\ 5HVXOWV LQ6WXG\
([SORUDWRU\HIILFDF\GDWDLQSVRULD VLV3$6,VWDWLF3*$>V3*$@ ZHUHREWDLQHGLQ
6WXG\7KLVVWXG\KDGDVPDOO VDPSOHVL]HVXEMHFWV FRQWULEXWHGWRHIILFDF\GDWD
DQGWUHDWPHQWGXUDWLRQZDV OLPLWHGWRGD\V$WRWDORIVX EMHFWV IRUPJ IRU
PJ IRUPJDQG1 IRUSODF HERZHUHLQFOXGHGLQWKH HIILFDF\DQDO\VLVVHWZKLFK
LQFOXGHGVXEMHFWVZKRKDG3$6,DQG RUV3*$GDWDDW'D\DQG'D \(IILFDF\GDWDZHUH
FRPSOHWHIRUWKHVHVXEMHFWV DQGQRLPSXWDWLRQZDVQHHGHGIR UPLVVLQJGDWD
x7UHDWPHQWZLWK1',VKRZH GDGRVHGHSHQGHQWWUHQGLQUHGX FWLRQRIGLVHDVH
VHYHULW\ZLWKPHDQSHUFHQWUHGXF WLRQIURP3$6,VFRUHDW'D\ FRPSDUHGWR'D\RI
x3$6,ZDVDFKLHYHGLQ DQGLQ WKHDQGPJ
JURXSVUHVSHFWLYHO\FRPSDUHGW RLQWKHSODFHERJURXS 
x3$6,ZDVDFKLHYHGLQVXEM HFWLQWKHPJJURXS EXWQRWDFKLHYHGLQWKH
RWKHUJURXSV7KHVDPHVXEM HFWDOVRDFKLHYHG3$6,
x7UHDWPHQWZLWK1',DOVRLPS URYHGWKHV3*$VFRUHFRPSDUHG WRSODFHERZLWK
RQHVXEMHFWLQWKHPJFRKRUWDFK LHYLQJDQV3*$RIPLQLPDO GLVHDVHDW'D\
 6DIHW\5HVXOWVLQ6WXG\
7UHDWPHQWZLWK1',ZDVJHQH UDOO\VDIHDQGZHOOWROHUDWHG 7KHUHZHUHQRGHDWKVRU
VHULRXV$HV7($(VRFFXUUHGL QDQG RIVXEMHFWVUHFHLYLQJ
RUPJ1',FRPSDUHGZLWK RIVXEMHFWVLQWKH SODFHERJURXS$OO7($(V
ZHUHPLOG*UDGHRUPRGHUDWH *UDGHLQLQWHQVLW\H[FHSWI RURQHVHYHUH*UDGHDGYHUVH
HYHQWRIQHXWURSHQLDLQDVXEM HFWWUHDWHGZLWKPJRI1', WKDWOHGWRGLVFRQWLQXDWLRQRI
WUHDWPHQW7KLVHYHQWZDVREVHU YHGRQ'D\RIWUHDWPHQWUHVXOW LQJLQGLVFRQWLQXDWLRQRIVWXG\
GUXJRQ'D\7KHVXEMHFWÂ¶VQHXWU RSKLOFRXQWZDVQRUPDORQ'D \GD\VDIWHUWUHDWPHQW'RFX6LJQ(QYHORSH,'')')%)$&
PPD PPD PPD PPD
PPDPPD PPD
PPD
)RUQRQFRPPHUFLDOXVHRQO\WVFRQWVFRQ
VXEMHFWVXEMHFWV
OXGHGLQXGHGLQ
'D\DQ'D\
ZDVQHHGZDVQH
GRVHGHSRVHGH
QIURP3IURP
GLQGLRPPFRP
RQF
U QRQ
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RIZDVVWRSSHG7KH*UDGH QHXWURSHQLDZDVWKHRQO\DGYHUVHHYHQW FRQVWLWXWLQJ*UDGHRUKLJKHU
KHPDWRORJLFWR[LFLW\REVHUYHGL QWKLVVWXG\,WZDVGHHPHGUHOD WHGWRVWXG\GUXJEXWQRWVHULRXV
)XUWKHULQIRUPDWLRQRQFKDQJHVL QVDIHW\ODERUDWRU\WHVWVLQFO XGLQJF\WRSHQLDDQG EORRGFUHDWLQH
SKRVSKRNLQDVH&3. HOHYDWLRQLVSUHVHQWHGLQ 6HFWLRQ 7KHUHZHUHQRHYHQWVRIDFQHLIRUP
GHUPDWLWLVSDSXODUUDVKRUDSKW KRXVXOFHUUHSRUWHGLQWKLVVW XG\7KHUHZHUHQRFOLQLFDOO\
VLJQLILFDQWFKDQJHVLQYLWDOVL JQVSK\VLFDOH[DPRU(&*2QH VXEMHFWLQWKHPJFRKRUW
UHFHLYHGRQO\RQHGRVHRIVWXG\GU XJDQGGLVFRQWLQXHGWKHVWXG\ DIWHU'D\GXHWRDSRVLWLYH7%
WHVW 7KLVVXEMHFWZDVLQFOXGHGL QWKHVDIHW\DQDO\VLVVHWEXW QRWLQWKHHIILFDF\DQDO\VLV
 3KDUPDFRNLQHWLF5H VXOWVLQ6WXG\
 5LVN%HQHILW$VVHVVPHQW
 .QRZQ3RWHQWLDO5LVNV
1RLPSRUWDQWLGHQWLILH GULVNVKDYHHPHUJHG IURP&OLQLFDO6WXGLH VLQKHDOWK\YROXQWHHUV
RULQVXEMHFWVZLWKPRGHUDWH WRVHYHUHSODTXHSVRULDVL V
3RWHQWLDOULVNVEDVH GRQSUHFOLQLFDOILQGLQJV VHH,%IRUGHWDL OVLQFOXGHWDFK\FDUGLDDQG
LQFUHDVHGVHUXPELOLUXELQ7RGDWH QRFOLQLFDOO\VLJQLILFDQWL QFUHDVHVLQKHDUWUDWHRULQVHUXP
ELOLUXELQKDYHEHHQREVHUYH GLQ6WXGLHVRU9 LWDOVLJQV(&*DQGVHUXP
ELOLUXELQZLOOFRQWLQXHWREHP RQLWRUHGSHUSURWRFROLQ6WXG\ 
3RWHQWLDOULVNVED VHGRQREVHUYDWLRQVIURPFOLQLFDOVWXGLHV DQGRUPRGHOLQJ
RUGUXJLQWHUDFWLRQVDUHGHVFULEHGLQ 7DEOH$QDVVRFLDWLRQEHWZHH QWKHVDIHW\ILQGLQJV
FRQVLGHUHGSRWHQWLDOULVNVD QGXVHRIWKHVWXG\GUXJKDVQRWEH HQHVWDEOLVKHGDQGUHTXLUHVIXUWKHU
HYDOXDWLRQ
7DEOH 3RWHQWLDO5LVNVRI1',
3RWHQWLDO5LVN 6XPPDU\RI'DWD5DWLRQDOHIRU5LVN 0LWLJDWLRQ6WUD WHJ\
&\WRSHQLD 2QH*UDGH$(RIQHXWURSHQLDRFFXUUHGLQD
VXEMHFWWUHDWHGZLWK1',PJGDLO\
LQ6WXG\ZKLFKUHVXOWHGLQ
GLVFRQWLQXDWLRQRIVWXG\PHGLFDWLRQ7KHDEVROXWHQHXWURSKLOFRXQWIRUWKLVVXEMHFW,Q6WXG\
6XEMHFWVZLWKDEVROXWHQHXWURSKLOFRXQWRI
[
/PPDUHH[FOXGHG
IURPSDUWLFLSDWLRQ'RFX6LJQ(QYHORSH,'')')%)$&
PPD
)RUQRQFRPPHUYHHPHUJHPH
PRGHUDWHPRGHUD
LQLFDLQ\QO\RQO\
VHRO XVH
FLDOXHUFLD
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI3RWHQWLDO5LVN 6XPPDU\RI'DWD5DWLRQDOHIRU5LVN 0LWLJDWLRQ6WUD WHJ\
UHWXUQHGWRQRUPDOZ LWKLQWKUHHGD\VRI
GLVFRQWLQXDWLRQRIVWXG\PHGLFDWLRQ
2YHUDOOVXEMHFWV WUHDWHGZLWK
1',DQGVXEMHFWWUHDWHG
ZLWKSODFHERH[SHULHQ FHGQHXWURSHQLDRI
*UDGHÂ•LQ6WXG\
VXEMHFWVWUHDWHGZLWK
1',DQGQRVXEMHFWVWUHDWHGZLWKSODFHERH[SHULHQFHGO\PSKRSHQLDRI*UDGHÂ•LQ6WXG\
1RFDVHVRIDQHPLDRUWKURPERF\WRSHQLDRI
*UDGHÂ•ZHUHQRWHGLQ6WXG\
1RVXEMHFWVWUHDWHGZLWK1',LQ6WXG\
H[SHULHQFHGDQ\F\WRSHQLDRI*UDGH Â•DQGWKHUHZHUHQRWR[LFRORJ\ILQGLQJVLQZHHNRUZHHNUDWRUPRQNH\VWXGLHVVXJJHVWLQJWKLVULVN6XEMHFWVZLWKDEVROXWHO\PSKRF\WHFRXQW
RI[
/PPDUH
H[FOXGHGIURPSDUWLFLSDWLRQ
:KLWHEORRGFHOOFRXQWDQGGLIIHUHQWLDOV
ZLOOEHPRQLWRUHGSHUSURWRFRO
&\WRSHQLDÂ•*UDGHLVDQ$(6,
,IWKH VXEMHFWH[SHULHQFHVD&7&$(*UDGH
Â•F\WRSHQLDDQHPLDOHXNRSHQLDQHXWURSHQLDO\PSKRSHQLDDQGWKURPERF\WRSHQLDFOLQLFDOO\VLJQLILFDQWRUQRWDVGHILQHGLQ 6HFWLRQ GRVLQJ
PXVWEH KHOG7KHVXEMHFWVKRXOGEH
IROORZHGZLWKSHULRGLFWHVWLQJXQWLOWKHODERUDWRU\YDOXHVUHWXUQWRQRUPDOUDQJHDWZKLFKWLPHGRVLQJPD\EHUHVXPHG,IWKHVDPHVXEMHFWGHYHORSV&7&$(*UDGHÂ•F\WRSHQLDIRUDVHFRQGWLPHDIWHU
GRVLQJLVUHVXPHGWKHQWKHVXEMHFW ZLOOEH
SHUPDQHQWO\GLVFRQWLQXHGIURPWUHDWPHQWEXWPD\EHFRQWLQXHGLQWKHWULDODQGIROORZHGXQWLOUHVROXWLRQRIWKHDEQRUPDOLW\
&3.HOHYDWLRQ *UDGHHOHYDWLRQVRI&3.RFFXUUHGLQ
VXEMHFWVRQ1',DQGSODFHERLQ
VWXGLHVDQG 1RFOLQLFDOO\
VLJQLILFDQWLQFUHDVHVL QVHUXPFUHDWLQLQHRU
DEQRUPDOLWLHVRQXULQDO\VLVDFFRPSDQLHGWKHVHHOHYDWLRQVLQ&3.7KHUHZDVQRDSSDUHQWWHPSRUDODVVRFLDWLRQZLWKDGPLQLVWUDWLRQRIVWXG\GUXJ,Q6WXG\
&3.ZLOOEHPRQLWRUHGSHUSURWRFRO&3.HOHYDWLRQÂ•*UDGHLVDQ$(6,
6XEMHFWVZLWKDGUXJUHODWHG6$(RUVHYHUH
GUXJUHODWHG$(PD\EHGLVFRQWLQXHGIURPVWXG\PHGLFDWLRQ
'UXJLQWHUDFWLRQ ,Q6WXG\
6WURQJDQGPRGHUDWHLQKLELWRUVRI
&<3$DUHSURKLELWHGLQ6WXG\
([FOXVLRQFULWHULDLQ6WXG\
HQVXUHDGHTXDWHZDVKRXWRIVWURQJDQGPRGHUDWHLQKLELWRUVRI&<3$'RFX6LJQ(QYHORSH,'')')%)$&
PPD
PPD)RUQRQFRPPHUFFXUUHGLQXUUHG
GSODFHERSODFHE
1
QVHUXPFUUXP
LQDO\VLVDQDO\VL
.7KHUH7KHUHUFLDOXVHRQO\FKK
VDPHVXDPHV
Â•F\WRSHF\WRS
GRVLQJGRVLQ
SHUPSH
EXV
FLDWLRQZLDWLRQHU
))
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI3RWHQWLDO5LVN 6XPPDU\RI'DWD5DWLRQDOHIRU5LVN 0LWLJDWLRQ6WUD WHJ\
$EEUHYLDWLRQV&3.FUHDWLQHSKRVSKRNLQDVH

0LOGHYHQWVRIDFQHLIRUPGHUP DWLWLVDQGVLPLODUHYHQWVZLWKLQW KHVNLQDQGVXEFXWDQHRXVWLVVXH
GLVRUGHUVV\VWHPRUJDQFODVV6 2&ZHUHFRPPRQO\REVHUYHGLQVX EMHFWVKHDOWK\YROXQWHHUV
WUHDWHGZLWK1',LQ6WXG\
1RHYHQWVRIDFQHLIRUPGHUPDWLWLVRUVLPLODUHYHQWVZLWKLQWKH VNLQDQG
VXEFXWDQHRXVWLVVXHGLVRUGHUV 62&ZHUHREVHUYHGLQVXEMHFWV WUHD WHGZLWK1',LQ6WXG\

 .QRZQ3RWHQWLDO%HQHILWV
1',KDVSRWHQWLDOWRWUHDW DYDULHW\RIDXWRLPPXQHDQGL QIODPPDWRU\GLVRUGHUV
LQFOXGLQJSVRULDVLV7KHVHGLVHDV HVSUHVHQWVHULRXVORQJWHUP KHDOWKULVNVZLWKVLJQLILFDQWXQPHW
PHGLFDOQHHG([SORUDWRU\H IILFDF\GDWDIURP6WXG\LQ VXEMHFWV ZLWKPRGHUDWHWR
VHYHUHSODTXH SVRULDVLV 6HFWLRQ  VXJJHVWWKDW1',PD\G HPRQVWUDWHHIILFDF\LQ
ODUJHUUDQGRPL]HGFRQWUROOHGV WXGLHVLQFOXGLQJSURSRVHG6WXG\ (IILFDF\GDWDIURP
3KDVHWULDOVRIWKHDOORVWHULF 7<.LQKLELWRUGHXFUDYDFLWLQLE GHPRQVWUDWHWKDWGHXFUDYDFLWLQLE
KDVVXSHULRUHIILF DF\WRDSUHPLODVWWKHRQO\)'$DSSURYHGRU DOPHGLFDWLRQIRU
PRGHUDWHWRVHYHUHSODTXHSVRULD VLV7KXVHDUO\FOLQLFDOGDWD IURP1',DQGSLYRWDOGDWD
IURP3KDVHVWXGLHVRIGHXFUDY DFLWLQLEDQRWKHUDOORVWHULF7<. LQKLELWRUVXSSRUWWKHSRWHQWLDO
IRU1',WRWUHDWPRGHUDWHW RVHYHUHSODTXHSVRULDVLV
 $VVHVVPHQWRI5 LVNVDQG%HQHILWV
1',KDVXQGHUJRQHQRQFOLQLFDOD QGFOLQLFDOGHYHORSPHQWD VGHVFULEHGLQWKHODWHVW
YHUVLRQRIWKH,%7KHFROOHF WLYHQRQFOLQLFDOVDIHW\SURILOHDQ GVDIHW\UHVXOWVRIWKHFRPSOHWHG
3KDVHVWXGLHVDQGKD YHQRWUHVXOWHGLQLGHQ WLILFDWLRQRIVDIHW\VLJQDOVDQG
VXJJHVWWKDW1',LVJHQHUD OO\VDIHDQGZHOOWROHUDWHG7 KHSRWHQWLDOULVNVDVVRFLDWHGZLWK
1',FDQEHPRQLWRUHGDQG PLWLJDWHGDVRXWOLQHGE\LQFO XVLRQH[FOXVLRQFULWHULD
PRQLWRULQJRIFOLQLFDOODERUDWRU \WHVWVDQGYLWDOVLJQVWUHDWP HQWGLVFRQWLQXDWL RQFULWHULDDQGE\
H[FOXVLRQRIFRQFRPLWDQWPHGLFD WLRQVWKDWPD\KD YHFOLQLFDOO\V LJQLILFDQWLQWHUDFWLRQZLWK
1','RFX6LJQ(QYHORSH,'')')%)$&
PPD
PPD
PPDPPD
PPD
)RUQRQFRPPHUFLDOXVHRQQVXEVXE
PLODUHYHODUHY
EMHFWVHFWVWU
HW\RIDX\RI
HVHQWVHVHQWV
\GDWDIGDWDIUII

GVWXGLGVWXGLH
7<.7RQO\
DO XVUFLDO
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
43 of 94 Efficacy data from the Phase 1 Study 4858-102 suggest the therapeutic potential of NDI-034858 
in moderate to severe plaque psoriasis. This is supported by Phase 2b and Phase 3 studies from 
deucravacitin ib which validated blockade of TYK2 as a therapeutic approach for treatment of 
moderate to severe plaque psoriasis.   
In summary, the collective preclinical and clinical evidence supporting the inhibition  of TYK2  as 
a therapeutic approach in psoriasis and the safety profile of NDI -034858 established to date in 
healthy volunteers and psoriasis subjects  provide a strong scientific and clinical rationale for 
pursuing development of NDI -034858 in subjects  with moderate to severe plaque psoriasis. The 
benefit /risk for further development of NDI-034858 in psoriasis is therefore warranted. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
44 of 94 3. OBJECTIVE S AND ENDPOINTS  
OBJECTIVES  ENDPOINTS  
Primary Objective  
To assess the efficacy of 
NDI-034858 orally 
administered QD at 2 mg, 5 mg, 15 mg, or 30  mg for 
12 weeks in subjects with moderate to severe plaque 
psoriasis  Primary Efficacy Endpoint  
â€¢ Proportion of subjects achieving PASI -75 at Week 12  
Secondary Efficacy Endpoints  
â€¢ Proportion of subjects achieving a PGA of clear (0) or almost clear (1) at 
Week 12  
â€¢ Proportion of subjects achieving at least PASI -90 at Week 12  
â€¢ Proportion of subjects achieving at least PASI -100 at Week 12  
â€¢ Change from baseline in DLQI at Week 12  
Exploratory  Endpoints  
  
  
  
  
  
  
  
  
 
  
 
  
  
  
 
 
  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
45 of 94 OBJECTIVES  ENDPOINTS  
Secondary Objectives  
To assess the safety and 
tolerability of NDI -034858 
orally administered QD at 2 mg, 5 mg, 15 mg, or 30  mg for 
12 weeks in subjects with 
moderate to severe plaque psoriasis  Secondary Safety  Endpoints  
â€¢ Incidence of A Es 
â€¢ Changes in vital signs, clinical laboratory parameters, and ECG s 
To evaluate the plasma 
concentration of NDI-034858 
orally administered QD at 2 
mg, 5 mg, 15 mg, or 30 mg 
in subjects with moderate to severe plaque psoriasis  Secondary Pharmacokinetic  Endpoint  
â€¢ Measurement of plasma concentrations of NDI -034858  in subjects 
receiving active treatment   
  
 
 
 
 
 Explorat ory  Endpoints 
  
 
 
 
 
 
 Expl orator y  Endpoints 
  
 
 
 
 
 
   
Abbreviations: AE, adverse event; ; DLQI, Dermatology Life Quality Index; 
ECG,  electrocardiogram; ; PASI, Psoriasis Area 
and Severity Index; PASI -100, 100% improvement from baseline in PASI;  
; PASI -75, 75% improvement from baseline in PASI; PASI -90, 90% improvement  from baseline 
in PASI; PGA, P hysicianâ€™s G lobal A ssessment; QD, once daily.  
  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI 678'<'(6,*1
 2YHUDOO'HVLJQ
7KLVLVD3KDVHEUDQGRPL]H GPXOWLFHQWHUGRXEOHEOLQGSODF HERFRQWUROOHGPXOWLSOH
GRVHVWXG\GHVLJQHGWRHYDOXDWH WKHHIILFDF\VDIHW\DQGWROH UDELOLW\ RI1',LQVXEMHFWV
ZLWKPRGHUDWHWRVHYHUHSODTXH SVRULDVLV7KLVVWXG\ZLOODOVR HYDOXDWHWKHSODVPDFRQFHQWUDWLRQV
RI1',DQGH[SORUHWKH LPPXQHUHVSRQVHLQEORRGDQGVNL QWR1',LQVXEMHFWV
ZLWKPRGHUDWHWRVHYHU HSODTXHSVRULDVLV
$SSUR[LPDWHO\PDOHDQGIHP DOHVXEMHFWVDJHGWR\HDUV LQFOXVLYHZLWKPRGHUDWHWR
VHYHUHSODTXHSVRULD VLVZLOOEHUDQGRPL]HGLQWKLVVWXG\7REH HOLJLEOHIRUWKHVWXG\WKHVXEMHFWV
ZLOOQHHGWRKDYHDKLVWRU\RISOD TXHSVRULDVLVIRUDWOHDVW PRQWKVSULRUWRWKHVFUHHQLQJYLVLW,Q
DGGLWLRQWKHVXEMHFWVZLOOQHHGW RKDYHWKHIROORZLQJFKDUDFWH ULVWLFVDWVFUHHQLQJDQGRQ'D\
3$6,VFRUHÂ•3*$VFRUHÂ• DQG%6$LQYROYHGZLWKSODTXHSV RULDVLVÂ•
$OOVXEMHFWVZLOOUHDGDQGVL JQDQ,&)SULRUWRDQ\VFUHHQLQJS URFHGXUHVEHLQJSHUIRUPHG
6XEMHFWVZKRIXOILOODOOLQFOXV LRQFULWHULDDQGQRQHRIWKHH[F OXVLRQFULWHULDZLOO EHLQFOXGHGLQWR
WKHVWXG\'XULQJDVFUHHQLQJSH ULRGRIQRORQJHUWKDQ'D\ WR'D\VXEMHFWVZLOOEH
UDQGRPL]HGRQ'D\WRUHFHLYH HLWKHURQHRIWKHIRXUGRVHV RI1',PJPJ
PJRUPJRUSODFHERRQ'D \7KHJRDOLVWRKDYHDSSU R[LPDWHO\VXEMHFWV
UDQGRPL]HGSHUWUHDWPHQWJURXS UDWLRRQ'D\'XUL QJWKHWUHDWPHQWSHULRG1',
PJPJPJRUPJRUSO DFHERZLOOEHRUDOO\ DGPLQLVWHUHG4'IRUZHHNV
7KHZHHNWUHDWPH QWSHULRGZLOOEHIROOR ZHGE\DZHHNVDIHW \IROORZXSSHULRG7KH
FRQGXFWRIWKHVW XG\LVLOOXVWUDWHGLQ )LJXUH
)RUVFKHGXOHGVWXG\YLVLWVVXEM HFWVZLOOFRPHWRWKHVWXG\VLW HRQRFFDVLRQVVFUHHQLQJ'D\
DQG:HHNV(27DQG(26(7
(IILFDF\ZLOOEHDVVHVVH GXVLQJ3$6,3*$
4XDOLW\RIOLIHZ LOOEHHYDOXDWHG
XVLQJ'/4,
6DIHW\ZLOOEHDVVHVVH GE\FROOHFWLQJ$(VUHFRUGLQJYLWDOVLJQ VSHUIRUPLQJSK\VLFDO
H[DPLQDWLRQVDQGHYDOX DWLQJFOLQLFDOODERUDWRU\DQG(&*VUHVXO WV
%ORRGVDPSOHVZLOOEHFROOHFWHGW RPHDVXUHSODVPD OHYHOVRI1', DVIROORZV
x2Q'D\SULRUWRGRVLQJD QGKRXUÂ“PLQSRVWGRVLQJ
x$W:HHNSULRUWRGRVLQJKRXUÂ“PLQSRVWGRVLQJDQGK RXUVÂ“PLQ
SRVWGRVLQJ
x$W:HHN SULRUWRGRVLQJ
x$W:HHNDQ\WLPHQRVWXG\WUHDWPH QWDGPLQLVWUDWLRQDWWKLVY LVLW
x$W(7YLVLWDQ\WLPHLI(7YL VLWLVSODQQHGEHIRUH:HHNYLVL W
'RFX6LJQ(QYHORSH,'')')%)$&
PPD)RUQRQFRPPHUFLDOXVHRQO\FHGXG
VLRQFULRQFU
WR'WR
GRVHVRRVHV
RKDYHKDYHDS
Q'D\'D\
ERZLOOERZLOO
HGE\DGE\D
H
LOOFRPHFRP
G(2
J3$6,33$6,
)RU
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
47 of 94  
  
 
 
 
 
 
 
 
 
 
 
. 
At certain  study sites, i n a subset  of subjects who consent , optional medical photographs of full -
body, front and back, will be taken to illustrate the outcome of the study. 
No interim analysis is planned in this study.  
4.2. Study Conduct During the Coronavir us Disease 2019 Pandemic  
Because of  the COVID -19 pandemic that has had a worldwide impact, including in North 
America, control measures in place in different regions may impact the ability to adhere to some 
of the study procedures described in this protocol. Due to challenges that include, but are not 
limited to, subject  preferences, site closures, travel restrictions, and quarantines, some 
modifications to study conduct during the COVID- 19 pandemic may be necessary to ensure 
study continuity.   
The following are allowable, as necessary, modifications to study conduct during the COVID-19 
pandemic.  
â€¢ Prior to a study visit at the study site, the subject  may be contacted and screened for 
potential exposure or infection to COVID- 19 per site, local , or fede ral requirements. 
If the subject  is suspected to be exposed or infected with COVID-19, the on- site visit 
should either be rescheduled or a virtual visit may be performed instead, as applicable 
(refer to Section 7.1 and  Section  7.2 for details on subject discontinuation from study 
treatment and study, respectively ).   
â€¢ If a subject  cannot attend their regularly scheduled study visits in person due to 
COVID- 19 necessitating a limit on in -person contact, the investigator may perform 
safety and other feasible assessments by phone or video, except for the screening, 
Day 1, and Week  12 visits. If the screening visit cannot be performed on- site, the 
subject  should not be screened. If the Day 1 visit cannot be performed on- site, the 
subject  should be considered to have failed screening. Subject s who failed screening 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
48 of 94 due to COVID- 19 restrictions at screening or Day 1 may be rescreened at a later time, 
if feasi ble.  
â€¢ Protocol deviations due to missed study visits, missed doses, or missed study 
procedures as well as study discontinuations due to COVID-19 restrictions should be 
documented accordingly. 
â€¢ Subjects  should continue recording their study product administration  via the Diary. 
Safety must be assessed during the virtual visit by collecting AEs and concomitant medications. Other safety or efficacy assessments may be performed as reasonably practicable.   
â€¢ Clinical laboratory tests (serum chemistries, hematology, and urinalysis) and 
pregnancy tests may be performed in local laboratory if these procedures cannot be performed at the study site due to COVID-19 related limitations, including but not 
limited to site closure. Clinically significa nt abnormal laboratory results should be 
promptly communicated to the m edical monitor within 72 hours of receipt, as per 
investigatorâ€™s judgment. S ubjects â€™ anonymity must be maintained when 
communicating results to the medical monitor. 
â€¢ Source documentation should note that the visit was performed virtually (not --face-
to-face) and note the name of the local laboratories where laboratory tests were done.  
â€¢ In the case of virtual visits, where the subject  is unable to attend the scheduled visits 
due to extenuating circumstances, such as quarantine or immobilization , study 
product may be shipped direct- to-subject from the site. Direct--to-subject  shipments 
should only occur if the investigator deems it safe for the subject  to continue study 
drug treatment. In all cases, requirements under local  regulations for maintaining 
required study product storage conditions and study product accountability remain.  
A detailed assessment of COVID -19 related risk and mitigation measures will be documented in 
the appropriate study plans. 
4.3. Scientific Rationale for Study Design  
The proposed design is considered appropriate for assessing the efficacy, safety, and tolerability 
of NDI -034858 (at 2 mg, 5 mg, 15 mg, or 30 mg ) compared with placebo in subjects with 
moderate to severe plaque psoriasis .  
This Phase 2b study will be randomized to ensure random allocation of subjects to treatment 
groups to reduce bias. Randomization will be stratified based on prior treatment with biologics. 
Because efficacy assessments of plaque psoriasis  have a high degree of subjectivity, the study 
will be double-blinded. The highest degree of subject and study site assessor blinding should be sought to achieve credible inference. It is also important to have a placebo control in this Phase 
2b study to control for confounding factors, such as potential investigator bias, and to ensure that 
the statistical procedures can be appropriately applied.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI -XVWLILFDWLRQIRU'RVH
'RVLQJUHJLPHQVIRUWKLV3KDV HGRVHUDQJLQJVWXG\ZHUHVHOHFW HGZLWKWKHREMHFWLYHRI
HVWDEOLVKLQJDGRVHH[SRVXUHUH VSRQVHRI1',DQG3$6,VF RUHLQVXEMHFWVZLWKPRGHUDWH
WRVHYHUHSODTXHSVRULDVLV6 XEMHFWVHQUROOHGLQWKLVVWXG\ZLO OUHFHLYHRQHRIILYHWUHDWPHQWV
SODFHERPJ1',GDLO\ PJ1',GDLO\PJ1' ,GDLO\DQG
PJ1',GDLO\'RVHUHJ LPHQVZHUHVHOHFWHGEDVHGRQWK HSUHFOLQLFDODVVHVVPHQWRI
1',DQGH[SORUDWRU\DVVHVVPHQ WRI3.3'FRUUHODWLRQLQ ILUVWLQKXPDQ),+6WXG\

7KHSULPDU\3'PHDVXUHPHQWXVH GIRUGRVHVHOHFWLRQLQSVRULDVLV ZDVWKHLQKLELWLRQRI,/
LQGXFHG,)1È–SURGXFWLRQPHDVXUHGLQDQ H[YLYRDVVD\LQWKH),+,WLVDVVXPHGWKDWWKH
LQKLELWLRQRI,/D VVD\DQGDGHTXDWHFRYHUDJHRIKDOIPD[L PDOLQKLELWRU\FRQFHQWUDWLRQ
,&DUHDVVRFLDWHGZLWKHIILF DF\LQSVRULDVLV7KLVDVVXPSWL RQLVVXSSRUWHGE\SUHFOLQLFDO
VWXGLHVRI1',DQGWKHFOLQL FDOLPSURYHPHQWVREVHUYHGLQ SVRULDVLVFOLQLFDOVWXGLHV
FRQGXFWHGXVLQJELRORJLFWKHUDSLHV GLUHFWHGDJDLQVWHLWKHUWKH SVXEXQLWRI,/RUWKHS
VXEXQLWLWVKDUHVZLWK,/H JXVWHNLQXPDEDVZHOODVFOLQ LFDOVWXGLHVFRQGXFWHGXVLQJ
FRPSRXQGVWKDWWDUJHWWKHVDP HSDWKZD\LQFOXGLQJ%06
8VLQJWKH3.DQG3'GDWDIURP WKH6$'DQGPXOWLSOHGRVLQJSRUWL RQVRIWKH),+VWXGLHV
QRQOLQHDUUHJUHVVLRQZDVXVHGWRFKD UDFWHUL]HWKHFRQFHQWUDWLRQ UHVSRQVHUHODWLRQVKLSLQWKH),+
VWXG\
:LWKWKHDVVXPSWLRQWKDW WKH,&VKRXOGEHVLPLODU
EHWZHHQKHDOWK\DQGSVRULDVLVVXEM HFWV WKHSURMHFWHGWURXJK
FRQFHQWUDWLRQ& WURXJKFRQFHQWUDWLRQVDUHH[SHFWHG WRFRYHUEHWZHHQLQKLELWRU\
FRQFHQWUDWLRQ,&DQGLQKL ELWRU\FRQFHQWUDWLRQ,&
7KHGRVHUDQJHSURSRVHGIRUWKH 3KDVHVWXG\ZLOOQRWH[FHHGW KHUDQJHRIGRVHVWHVWHGLQWKH
6$'SRUWLRQVRIWKH),+ PJQRUZLOOLWH[FHH GWKHUDQJHRIGRVHVWHVWHGLQ
WKHPXOWLSOHGRVHSRUWLRQRIW KH),+VWXG\PJ 4''HWDLOVRIWKHVDIHW\
SURILOHRIWKHPROHFXOHL QWKHDQGVWXGLHVDU HGLVFXVVHG 6HFWLRQ  
)XUWKHUPRUHWKHH[SHFWHG$8& WDXDQG& PD[UHVXOWLQJIURPWKHVHWUHDWPHQWOHYHOVDUHZLWKLQWKH
REVHUYHGSUHFOLQLFDODQGFOLQL FDOH[SRVXUHVVSDQQHGE\VWXGLHV DQG 
%DVHGRQWKHWRWDOLW\RIVDIHW\SKD UPDFRNLQHWLFDQGSKDUPDFRG\ QDPLFGDWDIURP WKH3KDVH
VWXGLHVWKHVHOHFWHGUDQJHIRUW KHSUHVHQWVWXG\LQFOXGHVGRVH VEHWZHHQPJDQGPJ'RFX6LJQ(QYHORSH,'')')%)$&
PPD
PPD
PPD
PPD)RUQRQFRPPHUFLDOXVHRQO\DOOVWXGVWX

RVLQJSRVLQJ
FHQWUDWLRHQWUDWL
WKHDVVXKHDVV
H[SHFWHG[SHFW
U\FRQFHFRQF
WKH3KDVWKH3K
FLDO
PPHU
RQFQRQ
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
50 of 94 4.5. End of Study Definition  
A subject is considered to have completed the study if he or she has completed all phases of the 
study, including the last visit or the last scheduled procedure shown in the Schedule of Events, Table 1. 
The end of the study is defined as completion of the last visit or procedure shown in the schedule 
of event for the last enrolled subject in the study globally for all study site s. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
51 of 94 5. STUDY POPULATION  
5.1. Inclusion Criteria  
In order to be eligible to participate in this study, a subject must meet all of the following criteria, 
either at the screening and Day 1 visits or only at one of the specified visits (screening or Day 1) as noted in the criterion: 
1. Male or female subject aged 18 to 70 years, inclusive, at the time of consent. 
2. Subject has a history of plaque psoriasis for at least 6 months prior to the screening visit. 
3. Subject had no significant flare in psoriasis for at least 3 months before screening 
(information obtained from medical chart or subjectâ€™s physician, or directly from the subject).  
4. Subject has moderate to severe plaque psoriasis as defined by a PASI score â‰¥ 12 and a PGA score â‰¥  3 at screening and Day 1. 
5. Subject has plaque psoriasis covering â‰¥ 10% of his or her total BSA at screening and 
Day 1. 
6. Subject must be a candidate for phototherapy or systemic therapy. 
7. For female subject s of childbearing potential involved in any sexual intercourse that 
could lead to pregnancy: the subject must agree to use a highly effective contraceptive 
method from at least 4 weeks prior to Day 1 until at least 4 weeks after the last study 
product administration. Highly effective contraceptive methods include hormonal contraceptives (eg, combined oral contraceptive, patch, vaginal ring, injectable, or 
implant), intrauterine devices or intrauterine systems, vasectomized partner(s) (provided 
vasectomy was performed â‰¥ 4 months prior to screening), bilateral tubal ligation  or 
occlusion, or double barrier methods of contraception (eg, male condom with cervical 
cap, male condom with diaphragm, and male condom with contraceptive sponge) in 
conjunction with spermicide.  
Note: Subjects must have been on a stable dose of combined hormonal contraceptives for at least 4 weeks  before Day 1.  
Note: The above list of contraceptive methods does not apply to subjects who are abstinent for at least 4 weeks before Day 1 and will continue to be abstinent from penile -vaginal 
intercourse throughout the study. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the clinical study, and the preferred and usual lifestyle of the 
subject. Periodic abstinence (calendar, symptothermal, postovulation methods) is not acceptable.  
Note:  A female subject of nonchildbearing potential is defined as follows:  
â€“ Female subject who has had surgical sterilization (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy); 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
52 of 94 â€“ Female subject who h as had a cessation of menses for at least 12 months prior to the 
screening visit without an alternative medical cause, and an FSH test confirming 
nonchildbearing potential (refer to laboratory reference ranges for confirmatory 
levels) . 
8. Female subjects of childbearing potential ha ve had a negative serum pregnancy test at 
screening and negative urine pregnancy test at Day 1. 
9. For male subject s involved in any sexual intercourse that could lead to pregnancy, subject 
must agree to use one of the highly effective contraceptive methods listed in Inclusion 
Criterion 7, from Day 1 until at least 12 weeks after the last study product administration. 
If the female partner of a male subject uses any of the hormonal contraceptive methods 
listed above, this contraceptive method should be used by the female partner from at least 4 weeks before Day  1 until at least 12 weeks after the last study product administration.  
Note: Male subjects must refrain  from donating sperm from Day 1 until at least 12 weeks 
after the last study product administration. 
Note: No restrictions are required for a male subject who underwent a vasectomy at least 
4 months prior to screening and the procedure is documented. If vasectomy procedure is 
not documented or was performed less than 4 months prior to screening, male subject s 
must follow the same contraception and sperm donation requirements as for 
nonvasectomized subjects. 
10. Subject has a BMI within the range of 18 to 42 kg/m
2, inclusive (BMI  = weight 
[kg]/[height (m)]2), and total body weight >50 kg (110 lb). 
11. Subject is willing to participate and is capable of giving informed consent. Note: Consent must be obtained prior to any study- related procedures.  
12. Subjects must be willing to comply with all study procedures and must be available for the duration of the study. 
5.2. Exclusion Criteria  
A subject who meets any of the following criteria at the screening and/or Day 1 visits, as applicable, will be excluded from participation in this study:  
1. Subject is a female who is breastfeeding, pregnant, or who is planning to become pregnant during the study.  
2. Subject has evidence of erythrodermic, pustular, predominantly guttate psoriasis, or drug-induced psoriasis. 
3. Subject h as a history of skin disease or presence of skin condition that, in the opinion of 
the investigator, would interfere with the study assessments. 
4. Subject has immune-mediated conditions commonly associated with psoriasis, such as psoriatic arthritis, uveitis, inflammatory bowel disease, that require systemic treatment (including corticosteroids, immunosuppressants, or biologics).  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
53 of 94 Note: Subjects with immune -mediated conditions that do not require systemic treatment 
may be included in the study. Certain therapies such as NSAIDs may be permitted but 
should be discussed with the Medical Monitor prior to determination of subject eligibility. 
5. Subject has any clinically significant medical condition, evidence of an unstable clinical condition (eg, cardiovascular, renal, hepatic, hematologic, gastrointestinal, endocrine, 
pulmonary, immunologic, or local active infection/infectious illness), psychiatric 
condition, or vital signs/physical/laboratory/ECG abnormality that would, in the opinion of the investigator, put the subject at undue risk or interfere with interpretation of study results.  
6. Subject had a major surgery within 8 weeks prior to Day 1 or has a major surgery planned during the study. 
7. Subject has a history of Class III or IV congestive heart failure as defined by New York 
Heart Association Criteria.  
8. Subject has been hospitaliz ed in the past 3 months for asthma, has ever required 
intubation for treatment of asthma, currently require oral corticosteroids for the treatment of asthma, or has required more than one short-term (â‰¤ 2 weeks) course of oral corticosteroids for asthma within 6 months prior to Day 1. 
9. Subject has a history of cancer or lymphoproliferative disease within 5 years prior to Day 1. Subjects with successfully treated nonmetastatic cutaneous squamous cell or basal 
cell carcinoma and/or localized carcinoma in situ of the cervix are not to be excluded. 
10. Subject has a history of fever, inflammation, or systemic signs of illness suggestive of systemic or invasive infection  within 4 weeks prior to Day 1. 
11. Subject has an active bacterial, viral, fungal, mycobacterial infection, or other infection 
(including TB or atypical mycobacterial disease), or any major episode of infection that required hospitalization or treatment with intravenous antibiotics within 12 weeks prior to 
Day 1, or oral antibiotics within 4 weeks prior to Day 1.  
12. Subject has a history of chronic or recurrent infectious disease, including but not limited to chronic renal infection, chronic chest infection, recurrent urinary tract infection, fungal infection  (except for  superficial fungal infection of the nailbed), or infected skin wounds 
or ulcers.  
13. Subject has a history of an infected joint prosthesis or has received antibiotics for a suspected infection of a joint prosthesis if that prosthesis has not been removed or replaced.  
14. Subject has active herpes infection, including herpes simplex 1 and 2 and herpes zoster (demonstrated on physical examination and/or medical history) within 8 weeks prior to Day 1. 
15. Subject has a history of known or suspected congenital or acquired immunodeficiency state or condition that would compromise the subjectâ€™s immune status in the opinion of 
the investigator (eg, history of splenectomy, primary immunodeficiency). 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
54 of 94 16. Subject has positive results for HbsAg, anti -HBc, HCV, or HIV.  
17. Subject has clinical or laboratory evidence of active or latent  TB infection at screening.  
Note: Subjects with an history of active or latent TB will not be included in the study, 
unless documentation of prior and complete anti- TB treatment, appropriate in duration and 
type according to current local country guidelines, can be provided.  
Note: Subject will be evaluated  at screening  for latent TB infection with a QFT test. Latent 
TB is defined as a positive QFT test or two successive indeterminate QTF tests at 
screening.   
Note: The T -Spot.TB test  (TBT)  is an acceptable alternative to the QFT test in regions 
where the TBT  is standard practice for tuberculosis screening. The medical monitor 
should be informed  prior to using the TBT tes t in place of the QFT test. A negative TBT 
test is  required  if the QFT test is not performed . 
 
18. Subject with any of the following laboratory values at the screening visit: 
a. ALT or AST values â‰¥ 3 times  the ULN;  
b. Hemoglobin < 11.0 g/dL (< 110.0 g/L); 
c. White blood cell count < 3.5 x 109/L (< 3 500/mm3); 
d. Absolute neutrophil count of < 1.8 x 109/L (< 1800/mm3); 
e. Absolute lymphocyte count of < 1.0 x 109/L (< 1000/mm3); 
f. Platelet count < 100 x 109/L (< 100,000/mm3); 
g. Total bilirubin Ëƒ 2 times  the ULN.  
19. Subjects who have given > 50 ml of blood or plasma within 30 days of screening or 
> 500 mL of blood or plasma within 56 days of screening (during a clinical study or at a 
blood bank donation). 
20. Subject has used any topical medication that could affect psoriasis (including corticosteroids, retinoids, vitamin D analogues [such as calcipotriol], JAK inhibitors, or tar) within 2 weeks prior to Day 1.  
21. Subject has used any systemic treatment that could affect psoriasis (including oral, intravenous, intramuscular, intraarticular, intrathecal, or intralesional corticosteroids; oral 
retinoids; immunosuppressive /immunomodulating medication ; methotrexate; 
cyclosporine; oral JAK inhibitors; or apremilast) within 4 weeks prior to Day 1.  
Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed. 
22. Subject has received any UV -B phototherapy (including tanning beds) or excimer laser 
within 4 weeks prior to Day 1. 
23. Subject has had PUVA treatment within 4 weeks prior to Day 1. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
55 of 94 24. Subject has received any live- attenuated vaccine within 4  weeks prior to Day 1 or plans 
to receive a live- attenuated v accine during the study and up to 4 weeks or 5 half-lives of 
the study product, whichever is longer, after the last study product administration.  
Note: Non-live-attenuated vaccines or boosters for COVID -19 (eg, RNA- based vaccines, 
inactivated adenovirus-b ased vaccines, protein -based vaccines) are allowed during the 
study. The study site should follow local guidelines related to COVID-19. 
25. Subject is currently receiving a nonbiological investigational product or device or has 
received one within 4 weeks prior to Day 1. 
26. Subject has received any marketed or investigational biological agent within 12 weeks or 5 half -lives (whichever is longer) prior to Day 1 (except those listed in Exclusion 
Criterion 27 and 28 that are to be excluded for 6 months). 
27. Subject was previously enrolled in any study with NDI-034858. 
28. Subject has a history of lack of response to any therapeutic agent targeting IL- 12, IL -17, 
and/or IL-23 (eg, ustekinumab, secukinumab, ixekizumab, brodalumab, guselkumab, 
tildrakizumab, risankizumab) at approved doses after at least 12 weeks of therapy, and/or received one of these therapies within 6 months prior to Day 1. 
29. Subject h as received rituximab or other immune -cell depleting therapy within 6 months. 
30. Subject is currently being treated with strong or moderate cytochrome P450 3A (CYP3A4) inhibitors (such as itraconazole , refer to Appendix 1), or has received 
moderate or strong CYP3A4 inhibitors within 4 weeks prior to Day 1. 
31. Subject is currently being treated with terbinafine or has received terbinafine within 4 weeks prior to Day 1. 
32. Subject has consumed grapefruit within 1 week prior to Day 1. 
Note: Consumption of grapefruit must be avoided during the treatment period and for at least 1  week after last dose administration.  
33. Subject has  used tanning booths within 4 weeks prior to Day 1, has had excessive sun 
exposure, or is not willing to minimize natural and artificial sunlight exposure during the study.  
Note: Use of sunscreen products and protective apparel are recommended when sun 
exposure cannot be avoided. 
34. Subject has a known or suspected allergy to NDI-034858 or any component of the investigational product, or any other significant drug allergy (such as anaphylaxis or hepatotoxicity). 
35. Subject has a known history of clinically significant drug or alcohol abuse in the last year prior to Day 1. 
36. For subjects consenting to biopsy collection only:  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
56 of 94 â€“ Subject has a history of an allergic reaction or significant sensitivity to lidocaine or 
other local anesthetics.  
â€“ Subject has a history of hypertrophic scarring or keloid formation in scars or suture sites.  
â€“ Subject has taken anticoagulant medication, such as heparin, LMW-heparin, warfarin, 
or antiplatelet agents (except low -dose aspirin â‰¤ 81 mg which will be allowed), within 
2 weeks prior to Day 1, or has a contraindication to skin biopsies. Nonsteroidal anti-inflammator y drugs will not be considered antiplatelet agent s and will be allowed. 
5.3. Screen Failures  
Screen failures are defined as individuals who consent to participate in the clinical study but are not subsequently randomly assigned to the study treatment. A minimal set of screen failure information is required to ensure transparent reporting of screen failure subjects, to meet the 
Consolidated Standards of Reporting Trials publishing requirements, and to respond to queries 
from regulatory authorities. Minimal information includes demography, screen failure details, and eligibility criteria.  
Individuals who do not meet the criteria for participation in this study (screen failure) may be rescreened once, if deemed acceptable by the investigator. Rescreened subjects sho uld be 
assigned a different subject number than the initial screening. All procedures planned at the screening visit, including signature of a new consent form, will be performed. 
 
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
57 of 94 6. TREATMENT  
6.1. Study Treatment Administered  
This study involves a comparison of NDI -034858 at 2 mg, 5 mg, 15 mg, or 30 mg orally 
administered QD with a placebo . NDI -034858 will be available in 2 mg, 5 mg, and 15 mg 
strength capsules. All study products will be provided by the sponsor. 
All study products will be administered orally daily , as assigned, for 12 weeks. On study days, 
the study products will be administered at the study site (if applicable) . The date and time of the 
drug administration will be collected daily by the study site  (during the visit)  or via a diary  
provided to the subject. The subject should be instructed to take the study product at 
approximately the same time of the day. For Day  1 and Week 12 visits, subjects  should be fasted 
for at least 8 hours before their visit and up to the time of the blood draw for fasting lipid panel.  
Further details regarding the study products can be found in Table 3. 
Table 3: Study Treatment s 
 Study Products  
Product name  NDI-034858  NDI-034858  NDI-034858  NDI-034858  Placebo  
Dosage form Capsule Capsule Capsule Capsule Capsule 
Unit dose 
strength(s)  2 mg  5 mg  15 mg  15 mg  N/A 
Dosage level(s)  2 mg  5 mg  15 mg  30 mg  N/A 
Number of 
capsules per 
dose level  1 active 
1 placebo 1 active  
1 placebo 1 active  
1 placebo 2 active  2 placebo 
Route of administration 
 Oral Oral Oral Oral Oral 
Dosing instructions  QD with 
approximately 
240 mL of 
water  QD with 
approximately 
240 mL of 
water  QD with 
approximately 
240 mL of 
water  QD with 
approximately 
240 mL of 
water  QD with 
approximately 
240 mL of water 
Physical description  Opaque white 
capsules  Opaque white 
capsules  Opaque white 
capsules  Opaque white 
capsules  Placebo is 
identical to the 
active capsules in 
size, shape, and 
color. 
Source of 
procurement  Nimbus 
Lakshmi, Inc.  Nimbus 
Lakshmi, Inc.  Nimbus 
Laks hmi, Inc.  Nimbus 
Lakshmi, Inc.  Nimbus 
Lakshmi, Inc.  
Abbreviation s: N/A, not applicable ; QD, once daily . 
The contents of the label will be in accordance with all applicable regulatory requirements . 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
58 of 94 6.2. Preparation/Handling/Storage/Accountability  
6.2.1. Preparation /Storage/Handling  
All study products must be stored in a secure environmentally controlled and monitored area in 
accordance with the labelled storage conditions with access limited to the investigator and 
authorized site staff. The study products may only be supplied by authorized site staff and may 
only be given to subjects enrolled into the study.   
Study product s will be dispensed by the study site to the subject at the visits specified in  Table 1. 
Subjects are to return all study products (used and unused) to the study site. The capsules will be 
counted prior to dispensing and upon return, and the counts will be recorded in the source 
documents and electronic case report form  (eCRF ). Each subject will be instructed on the 
importance of returning study product at the next study visit and on taking the product as prescribed. If a subject does  not return study product, he or she will be instructed to return it as 
soon as possible. 
6.2.2. Accountability  
The investigator is responsible for maintaining accurate records of the study product received 
initially  and of the study product dispensed/used. Any study product accidentally or deliberately 
destroyed or returned to the sponsor or designee will be accounted for. Any discrepancies 
between amounts dispensed and returned will be explained. At the conclusion of the study, all 
used and unused investigational products, and all medication containers will be returned or destroyed as per approved arrangements by the sponsor.   
All study product accountability forms and treatment logs must be retained in the investigatorâ€™s 
study files. Product inventory and accountability records will be maintained , as per ICH GCP . 
These records must be available for inspection at any time by the sponsor, its designees, or by 
regulatory agencies.  
Further guidance and information for final disposition of study products are pro vided in the study 
manual . 
6.3. Randomization  
At the study site, each screened subject will be assigned a subject identifier number during 
screening that will be used on all subject documentation. The subject identifier number will 
contain the site number and the subject number and will be assigned in numerical order at the screening visit based on chronological order of screening dates (eg, 02-010 for the 10
th subject 
screened at Site 02). 
Approximately 250 subjects will be randomized 1:1:1:1:1 ratio to NDI -034858 at 2 mg, 5 mg, 
15 mg, or 30 mg, or placebo (approximately 50 subjects per treatment group).  
Randomization will occur at Day -7 visit.  Before Day -7, available eligibility information will be 
reviewed and Subject Eligibility Form will be submitted for approval. Subject will then be 
randomized.   The randomization list will be generated using validated  software  and will be 
stratified based on prior treatment with biologics (yes/no). The  master  randomization list will be 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
59 of 94 kept secured until the study blind is broken at the end of study. This list will be upload ed into an 
Interactive Web Response System  (IWR S). The investigator or designee will be able to acquire a 
randomizatio n number for subjects by connecting to the IWRS. Of note, only eligible subjects 
(confirmed on Day 1) will receive the study treatment.  
A cap on the number of subjects to include for optional biopsy collection and optional tape strips 
will be placed between 30% to 50% and 40% to 60%, respectively. 
Further guidance and information can be obtained in the study manual. 
6.3.1. Blinding  
This study will be double-blinded. At all times, treatment and randomization information will be 
kept confidential and will not be released to the investigator, the study staff, the contract research 
organization ( CRO ), or the sponsorâ€™s study team until after the conclusion of the study. 
Breaking the blind should be considered only when knowledge of the treatment assignment is 
deemed essential for the subjectâ€™s care. In such case of a medical emergency, the investigator has the sole responsibility for determining if unblinding of a subjectâ€™s treatment assignment is warranted. Subject  safety must always be the first consideration in making such a determination. 
If the investigator decides that unblinding is warranted, the investigator should make every effort to contact the medical monitor prior to unblinding a subjec tâ€™s treatment assignment unless this 
could delay further management of the subject . If a subject â€™s treatment assignment is unblinded, 
the medical monitor and the sponsor must be notified within 24 hours after breaking the blind. 
The date and reason for breaking the blind must be documented in the source document and the 
eCRF.  
In cases of accidental unblinding, the investigator should contact the medical monitor and ensure every attempt is made to preserve the blind. Any request to unblind a subject for nonemergency purposes must be discussed with the medical monitor prior to unblinding. 
The subject for whom the blind has been broken for a safety- related reason will be permanently 
discontinued from the study treatment . The primary re ason for study treatment discontinuation 
(the event or condition which led to the unblinding) will be recorded. 
6.3.2. Study Treatment Compliance  
Study treatment compliance will be monitored at each visit. Adherence to treatment  will be 
assessed by direct questioning, review of the subject â€™s dosing diary, and by maintaining adequate 
study product dispensing and return records.  
Subject s who are significantly noncompliant with treatment  will be counseled and could be 
discontinued from the study, at the discretion of the investigator, following consultation with the 
sponsor. Significant noncompliance is defined as missing 3 consecutive doses (ie, 3 days in a 
row) or missing  a total of 10 doses, or an overdose as defined in Section  8.4.10.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
60 of 94 6.4. Concomitant Therapy  
All medications (including over-the-counter drugs, vitamins, herbal/natural products, and 
antacids) taken within 4 weeks prior to screening and throughout the study must be recorded. In 
addition, the last use of any prohibited medications before Day 1 must be recorded and fall 
within the timeframe described in the exclusion criteria . 
Medication entries may be captured as generic or trade  names . Trade names should be used for 
combination drugs. Entries should include as much as possible of the following information: the dose, unit, frequency of administration, route of administration, start date, end  date, and 
indication. If the medication is stopped or the dosage is  changed, these details must be recorded. 
6.4.1. Permitted Therapies  
6.4.1.1. Emollients  
Subjects can  apply an emollient of their choice (except those containing salicylic acid) on their 
skin, including on psoriasis lesions . However, on the day of scheduled visits, subjects cannot 
apply emollient before their scheduled visit time.  
Every effort should be made to keep the same emollient throughout the study for the same body region. However, the chosen emollient may differ depending on the body region (eg, body vs face emollient may be different). The commercial name of the selected emollient (s) will be 
recorded in the source document and the eCRF. No other products may be applied to the lesions 
during the study. 
6.4.1.2. Other Permitted Therapies  
The following therapies are permitted: 
â€¢ Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear  drops 
containing corticosteroids are also allowed.   
â€¢ Use of sunscreen products and protective apparel are permitted when sun exposure 
cannot be avoided. However, on the day of scheduled visits, subjects cannot apply 
sunscreen products before their scheduled visit time. 
6.4.2. Prohibited Therapies or Procedures  
Table 4 lists prohibited medications that are not to be used from the defined washout periods 
before the first administration  of study treatment at the Day 1  visit through the last study visit. 
Subjects who start prohibited medications (systemic and topica l) or therapies during the study 
may be discontinued from study treatment. Section 7.1 provides the list of prohibited 
medications for which a subject must be permanently discontinued from the study. Investigators should contact the medical monitor as soon as possible when any prohibited medication  or 
therapy  is initiated, to  discuss the appropriate steps.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
61 of 94 Table 4: Prohibited Therapies or Procedures  
Prohibited Medications, Products, And Procedures  Washout Period Prior 
To First Dose ( Day 1)  
Therapeutic agent targeting IL -12, IL-17, and/or IL-23 (eg, ustekinumab, 
secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, 
risankizumab)  6 months 
Rituximab or other immune- cell depleting agents  6 months 
Any marketed or investigational biological agent  (except those listed 
above) 12 weeks or 5 half -lives 
(whichever is longer) 
Intravenous antibiotic treatment  12 weeks 
Oral antibiotic treatment  4 weeks 
Nonbiologic al investigational product or device  4 weeks 
Any live-attenuated vaccine 
Note: Non-live-attenuated vaccines or boosters for COVID -19 (eg, RNA-
based vaccines, inactivated adenovirus- based vaccines, protein -based 
vaccines) are allowed during the study. The study site should follow local guidelines related to COVID-19. 4 weeks 
Systemic treatment that could affect psoriasis (including oral, 
intravenous, intramuscular,  intraarticular, intrathecal, or intralesional 
corticosteroids ; oral retinoids ; immunosuppressive /immunomodulating  
medication ; methotrexate ; cyclosporine; oral JAK  inhibitors ; or 
apremilast)  
Note: Intranasal corticosteroids and inhaled corticosteroids are allowed. Eye and ear drops containing corticosteroids are also allowed.  4 weeks 
Strong or moderate CYP3A4 inhibitors (such as itraconazole), see Appendix 1 for a list of prohibited medications in this class.  4 weeks  
Terbinafine 4 weeks  
PUVA treatment, UV -B phototherapy (including tanning beds) , or 
excimer laser, or tanning booths 4 weeks 
Topical medication that could affect psoriasis (including corticosteroids, 
retinoids, vitamin D analogues [such as calcipotriol], JAK inhibitors,  or 
tar)  2 weeks  
For subjects consenting to biopsy collection only: Anticoagulant 
medication, such as heparin, LMW heparin, warfarin, or antiplatelet 
agent s (except low -dose aspirin â‰¤ 81 mg which will be allowed). 
Nonsteroidal anti- inflammatory drugs will not be considered antiplatelet  
agent s and will be allowed.  2 weeks 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
62 of 94 Prohibited Medications, Products, And Procedures  Washout Period Prior 
To First Dose ( Day 1)  
Grapefruit  
Note: Consumption of grapefruit must be avoided during the treatment 
period and for at least 1 week after last dose administration.  1 week  
Abbreviations: COVID -19, Coronavirus Disease 2019 ; CYP3A4, cytochrome P450 3A; IL, interleukin; JAK, 
Janus kinase; LMW, low molecular weight;  PUVA, psoralen -ultraviolet -A; UV, ultraviolet . 
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
63 of 94 7. DISCONTINUATION AND LOST TO FOLLOW- UP 
7.1. Discontinuation  from Study Treatment  
Medical judgment should be applied to guide whether study treatment  discontinuation or careful 
monitoring may be the most appropriate course of action. If it is deemed by the investigator that 
it is in the best interest of the subject  to discontinue further study treatment, the medical monitor 
should be contacted as soon as possible for consultation.  
Subjects must be permanently discontinued from study treatment for the following reasons: 
â€¢ Pregnancy of a female participant  
â€¢ The subject experiences a medical emergency that necessitates permanent 
discontinuation and/or unblinding of the subjectâ€™s treatment assignment 
â€¢ The subject is unwilling or unable to comply with the protocol 
â€¢ At the discretion of the investigator for medical reasons or noncompliance 
â€¢ Subject initiates any of the following prohibited medications ( Section  6.4.2):  
â€“ Therapeutic agent targeting IL -12, IL -17, and/or IL -23 (eg, ustekinumab, 
secukinumab, ixekizumab, brodalumab, guselkumab, tildrakizumab, risankizumab) 
â€“ Rituximab or other immune  cell depleting agents  
â€“ Other m arketed or investigational biological agent not listed above  
â€“ Live-attenuated vaccine  
Note: Non-live-attenuated vaccines or boosters for COVID -19 (eg, RNA- based 
vaccines, inactivated adenovirus-based vaccines, protein- based vaccines) are allowed 
during the study. The study site should follow local guidelines related to COVID-19.  
â€“ Nonbiological investigational product or device 
â€“ Intravenous antibiotic treatment 
â€“ Systemic treatment that could affect psoriasis (including oral, intravenous, 
intraarticular, intrathecal, or intramuscular  corticosteroids ; oral retinoids; 
immunosuppressive/immunomodulating medication; methotrexate ; cyclosporine; oral 
JAK inhibitors; or apremilast) . Intralesional injections are prohibited medications for 
the duration of the study; however, their use does not require  discontinuation from the 
study and should be discussed with the medical monitor to determine final subject 
disposition. 
â€¢ If the subject experiences a CTCAE Grade â‰¥2 cytopenia (anemia, leukopenia, 
neutropenia, lymphopenia, and thrombocytopenia; clinically significant or not) as defined 
in Section  8.4.7, for a second time after re- challenge, as detailed in the following 
paragraph. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
64 of 94 Subjects  must at least  be temporarily discontinued from study treatment  for the following 
reasons:  
â€¢ The subject experiences a CTCAE Grade â‰¥2 cytopenia (anemia, leukopenia, 
neutropenia, lymphopenia, and thrombocytopenia; clinically significant or not) as 
defined in Secti on 8.4.7. T he subject should be followed with periodic testing until 
the laboratory values return to normal range, at which time dosing may be resumed. If 
the same subject develops CTCAE Grade â‰¥2 cytopenia for a second time after dosing is resumed, then the subject will be permanently discontinued from treatment but may be continued in the trial and followed until resolution of the adverse event(s). 
â€¢ The subject has met study treatment discontinuation criteria for abnormalities suggestive of drug induced liver injury ( DILI ) as described in Section  8.4.8. 
Temporary discontinuation may or may not lead to permanent discontinuation of study treatment pending results of further workup and the overall clinical assessment. 
Subjects  may be discontinued from study treatment for any of , but not limited to,  the following 
reasons:  
â€¢ Occurrence of a drug -related SAE (see Section  8.4.2).  
â€¢ Occurrence of a severe drug-related AE (see Section  8.4.3).  
â€¢ Initiation of a protocol prohibited therapy or procedure ( Section  6.4.2) other than 
those for which the subject must be permanently discontinued from study treatment.  
Study procedures should be continued to be evaluated for safety, PK, and other parameters even 
in the event of dosing discontinuation. The medical monitor should be contacted for consultation, 
including if it may be appropriate to exclude any of the planned procedures. In the event a decision is made to permanently discontinue dosing and all other int erventions, please refer to 
the data to be collected at the ET visit of the schedule of events . 
7.2. Discontinuation from Study  
Subjects have the right to withdraw from the study at any time for any reason without penalty. 
The investigator also has the right to withdraw subjects from the study if he or she feels it is in 
the best interest of  the subject or if the subject is uncooperative or noncompliant.  
Should a subject decide to withdraw, all efforts will be made to complete and report the 
observations as thoroughly as possible, particularly the examinations outlined in the ET visit. 
The investigator or one of his or her staff members should contact the subject to determine as 
accurately  as possible the primary reason for the withdrawal.  
A complete fi nal evaluation at the time of the subjectâ€™s withdrawal should be made with an 
explanation of why the subject is withdrawing from the study. If the reason for removal of a subject is an AE or an abnormal laboratory test result, the principal specific event or test will be 
recorded.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
65 of 94 If a subject  withdraws from the study, he or she may request destruction of any samples taken 
and not tested, and the investigator must document this in the site study records. 
Subjects who discontinue the study after the first dose will be asked, if they agree, to come for a 
last assessment (ET visit).  Subjects who are discontinued for safety reasons may be asked to 
come for additional follow-up visits, at the investigatorâ€™s discretion, after the ET visit to ensure appropriate medical care and AEs follow -up. 
Subjects who discontinue after Day 1 dosing will not be replaced.  
Reasons for discontinuation may  include the following: 
â€¢ The investigator decides that the subject should be withdrawn. If this decision is made 
because of an SAE , the study product is to be discontinued in that subject 
immediately and appropriate measures are to be taken. The investigator will notify 
the sponsor immediately. 
â€¢ The subject, for any reason, requires treatment with another therapeutic agent that has been demonstrated to be effective for treatment of the study indication.  
â€¢ The subject fails to comply with other protocol requirements. 
â€¢ The subject is unable to continue visits or the study site is closed due to COVID-19 pandemic restrictions.  
â€¢ The subject is withdrawn for any medical condition or circumstance that exposes the 
subject to substantial risk and/or does not allow the subject to adhere to the requirements of the protocol. 
â€¢ The subject is lost to follow -up. In this case, a reasonable attemp t to contact the 
subject and ascertain his or her status must be made, and these attempts must be documented. 
â€¢ Other: the subject may withdraw from the study for any other reason, including withdrawal of consent. 
â€¢ Study termination by the sponsor or regulatory authorities (refer  to Section  7.4). 
7.3. Lost to Follow -Up 
A subject will be considered lost to follow-up if he or she fails to return for scheduled visits and 
is unable to be contacted by the study site staff.  
The following actions must be taken if a subject fails to return to the clinic for a required study 
visit (unless this is required by the COVID-19 situation and virtual visits are scheduled instead) : 
â€¢ The site will attempt to contact the subject and reschedule the missed visit. The site will then counsel the subject on the importance of maintaining the assigned visit schedule and ascertain if the subject wishes to or should continue in the study. 
â€¢ Before a subject is deemed lost to follow-up, the investigator or designee will make every effort to regain contact with the subject (where possible, three telephone calls 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
66 of 94 and, if necessary, a certified letter to the subjectâ€™s last known mailing address or local 
equivalent methods). These contact attempts should be documented in the subjectâ€™s medical record or study file. 
â€¢ If all attempts to contact the subject fail he or she will be considered to have withdrawn from the study with a primary reason of lost to follow-up. 
7.4. Study Termination  
The Sponsor has the right to terminate the study for any reason and at any time. Reasons for terminating the study may include, but are not limited to, the incidence or severity of TEAE in 
this or other studies indicating a potential health risk to participants. In this case, all subjects will 
be discontinued from the study. The investigator will immediately, on discontinuance of the 
study by the sponsor, in its entirety or at a clinical study site, inform both the subjects and the 
IRB/REB of the discontinuance, provide them with the reasons for the discontinuance and advis e 
them in writing of any potential risks to the health of subjects or other persons. The study can 
also be terminated by IRB and/or regulatory agency for any unforeseen reasons. 
  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
67 of 94 8. STUDY ASSESSMENTS  AND PROCEDURES  
8.1. Efficacy As sessments 
Clinical evaluations o f plaque psoriasis will be performed by an experienced and qualified 
dermatologist (board certified or equivalent) or other suitably qualified and experienced 
designee. To assure consistency and reduce variability, the same assessor should perform all 
assessments on a given subject whenever possible. 
8.1.1. Psoriasis Area and Severity Index  
The PASI  will be evaluated at the visits specified in  Table 1. This index quantifies the severity of 
a subjectâ€™s psoriasis based on both lesion severity and the percent age of BSA affected .15 The 
PASI is a composite score ranging from  0 to 72 that that takes into account the degree of 
erythema, induration/infiltration , and desquamation (each scored from 0 to 4 separately) for each 
of four body regions, with adjustments for the percentage of BSA involved for each body region 
and for the proportion of the body region to the whole body. Refer to  Appendix 2 for a complete 
description of this scale. To be eligible for this study, subjects must have a PASI score â‰¥ 12 at 
screening and Day  1 visit. 
8.1.2. Physicianâ€™s Global Assessment  
The PGA of disease severity will be assessed at the visits  specified in  Table  1. The PGA is a 
global assessment of the current state of the disease. It is a 5-point morphological assessment of 
overall disease severity . A detailed description of P GA16 scores is provided in  Table 5. To be 
eligible for this study, subjects must have a PGA score â‰¥ 3 at screening and Day 1 visit. 
Table 5: Physicianâ€™s Global Assessment  
Score Grade  Description  
0 Clear  No signs of psoriasis; post-inflammatory  hyperpigmentation may be present  
1 Almost clear  No thickening; normal to pink coloration; no to minimal focal scaling 
2 Mild  Just detectable to mild thickening; pink to light red coloration; 
predominantly fine scaling  
3 Moderate  Clearly distinguishable to moderate thickening; dull to bright red; clearly 
distinguishable to moderate erythema; moderate scaling  
4 Severe Severe thickening with hard edges; bright to deep dark red coloration; severe/coarse scaling covering almost all or all lesions  
8.1.3.  
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
68 of 94  
. 
8.1.4.  
  
 
 
 
. 
8.1.5.  
 
  
 
 
 
8.2. Quality- of-Life Assessments /Subject Reported Outcomes  
8.2.1. Dermatology Life Quality Index Questionnaire  
The DLQI will be assessed at the visits specified in  Table 1. It is a simple 10 -question validated 
questionnaire that has been used in more than 40 different skin conditions.21 Its use has been 
described in more than 1,000 publications, including many multinational studies. The DLQI is 
the most frequently used instrument in studies of randomized controlled studies in dermatology. 
The questionnaire is provided in Appendix 5.   
8.3. Safety and Other Assessments  
8.3.1. Vital Signs  
The following vital signs will be reco rded at the visits specified in Table 1 with the subject in a 
seated position, after having sat calmly for at least 5 minutes: systolic and diastolic blood pressure (mmHg), pulse (bpm), and body temperature (Â°C).  
Weight (kg) will be recorded at the visits  specified in  Table 1. Height (cm) will only be recorded 
once at the screening visit. 
Any abnormal finding related to vital signs that the investigator considers to be clinically 
significant must be recorded as an AE  starting  after dosing on Day 1.  
8.3.2. Physical Examination 
The following sites/systems will at least be included in the complete physical examination, 
which will be performed at the visits specified in  Table 1:  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
69 of 94 â€¢ General appearance  
â€¢ Dermatological (except plaque psoriasis) 
â€¢ Head, eyes , ears , nose, throat  
â€¢ Respiratory  
â€¢ Cardiovascular  
â€¢ Abdominal 
â€¢ Neurological 
â€¢ Musculoskeletal  
â€¢ Lymphatic 
Information for all physical examinations must be included in the source document. Any 
significant change will be reported as an AE in the source document and eCRF starting after 
dosing on Day 1.  
8.3.3. Targeted Physical Examination 
The following sites/systems will at least be included in the targeted physical examination that 
will be performed at the visits specified in  Table 1:  
â€¢ General appearance  
â€¢ Dermatological (except plaque psoriasis)  
â€¢ Respiratory  
â€¢ Cardiovascular  
â€¢ Abdominal 
If deemed appropriate by the investigator based on the subjectâ€™s condition, a complete physic al 
examination as described in Section 8.3.2 can be performed instead of a targeted examination.  
Information for all physical examinations must be included in the source document. Any significant change will be reported as an AE in the source document and eCRF starting after 
dosing on Day 1.  
8.3.4. Clinical Laboratory T ests 
Laboratory tests will be performed at the visits specified in  Table 1. The specific tests in these 
panels are listed in Table  6. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
70 of 94 Table 6: Clinical Laboratory Testing  
Laboratory Testing Tests Included  
Hematology  aPTT, HCT, Hgb, INR, MCH, MCHC, MCV, MPV, PLT, PT, RBC, WBC, 
and differentials (neutrophils, lymphocytes, monocytes, eosinophils, and 
basophils relative and absolute)  
Biochemistry  Albumin, alkaline phosphatase, ALT, AST, calcium , CPK, creatinine 
(enzymatic), GGT, glucose random, potassium, sodium, total bilirubin, direct 
bilirubin if total bilirubin > ULN , urea (BUN), uric acid  
Fasting lipids  Cholesterol (total, LDL, and HDL), t riglycerides (all fasting)  
Urinalysis  Color, clarity, pH, specific gravity, bilirubin, glucose, ketones, leukocytes, nitrite, blood, protein, urobilinogen 
Microscopic analysis (as required)  
Urine pregnancy test  
(conducted at the 
investigator site)  For WOCBP  (at each visit, except screening)  
Laboratory tests 
required at screening only FSH levels for female  subjects  who have had a cessation of menses for at 
least 12  months prior to the screening visit without an alternative medical 
cause  
Î²-hCG for WOCBP  
Tuber culosis test (QuantiFERON -TB Gold) 
â€¢ Note: A T-Spot.TB test (TBT) may be used as an alternative to the 
QuantiFERON-TB Gold test as per Exclusion Criterion 17. If the TBT  is used, the QuantiFERON-TB Gold test should not be 
performed. 
Serology (HBV [HBsAg, anti- HBc], HCV, HIV)   
Abbreviations: ALT , alanine aminotransferase; anti- HBc, anti body to hepatitis B core antigen ; aPTT , activated 
partial thromboplastin time; AST , aspartate aminotransferase; Î² -hCG , Î²-human chorionic gonadotropin; BUN , blood 
urea nitrogen ; CPK, creatine pho sphokinase ; FSH, follicle -stimulating hormone; GGT , 
gamma --glutamyl -transferase; HBsAg , hepatitis B surface antigens; HBV , hepatitis B virus; HCT , hematocrit; HCV , 
hepatitis C virus; Hgb, hemoglobin; HIV , human immunodeficiency virus; INR , international normalized ratio; 
LDH, lactate  dehydrogenase; MCH , mean corpuscular hemoglobin; MCHC , mean corpuscular hemoglobin 
concentration; MCV , mean corpuscular volume; MPV , mean platelet volume; PLT , platelets;  PT, prothrombin time; 
RBC, red blood cell (count);  ULN, upper limit of normal ; WBC, white blood cell (count) ; WOCBP, wom en of 
childbearing potential . 
 
In case of a screening laboratory value abnormality, the test can be repeated once within the 
original screening time window, if the investigator believes there is a reasonable possibility that 
the subject would be eligible if re -tested.  The QuantiFERON- TB test can only be repeated once 
if the result is indeterminate; tests with positiv e or negative results will not be repeated . The TBT 
may be used as an alternative to the QuantiFERON -TB test per Exclusion Criterion 17. The TBT 
may be repeated once only if the result  is borderline (equivocal) ; tests with positive or negative 
results will not be repeated.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
71 of 94 After  the subjectâ€™s first dose on Day 1, any clinically significant value will be reported as an AE . 
Any CTCAE Grade  â‰¥ 2 cytopenia (anemia, leukopenia, neutropenia, lymphopenia, or 
thrombocytopenia ; clinically significant or n ot) or CTCAE Grade â‰¥ 3 elevation of CPK 
(clinically significant or not) will be reported as an AE and AE SI (Section  8.4.7).  If a subject 
experiences a CTCAE Grade â‰¥2 cytopenia (anemia, leukopenia, neutropenia, lymphopenia, and 
thrombocytopenia; clinically significant or not) as defined in Section  8.4.7, dosing will be 
interrupted, and the subject followed with periodic testing until the laboratory values return to 
normal range. If the same subject develops a CTCAE Grade â‰¥2 cytopenia for a second time after 
dosing is resumed, then the subject will be permanently discontinued from treatment, but may be 
continued in the trial and followed until resolution of the adverse event(s). 
8.3.4.1. Use of Local Laboratories 
All protocol-specified laboratory tests (See Table 6) should be performed via the central 
laboratory. All attempts should be made to perform the laboratory a ssessments at the study site , 
via the central laboratory. In situations where the laboratory tests cannot be performed at the 
study site due to extenuating circumstances, such as quarantine or immobilization, the protocol-
specif ied laboratory examinations may be conducted through a local laboratory. If the TBT is 
used as an alternative to the QuantiFERON-TB Gold test as per Exclusion Criterion 17, it may 
be performed via a local laboratory.  
Use of local laboratories for any purpose beyond collection of protocol- specific laboratory tests 
that cannot be performed at central laboratory due to extenuating circumstances should be discussed with the medical monitor. Results from local laboratories will be recorded on the appropriate eCRF.  
Follow-up safety monitoring will be conducted at the investigatorâ€™s discretion . Results 
determined by the investigator to be SAEs or AESI, should be reported to the sponsor following 
the procedures described in Section  8.4.6, Section  8.4.7, and the Study Reference Manual, as 
applicable.  
8.3.5. Electrocardiogra m  
Twelve- lead ECGs will be performed as a safety assessment at the visits specified in  Table 1. 
Any clinically significant value will be reported as an AE starting on Day 1.  
8.3.6. Plasma Concentration of NDI -034858 
Blood samples will be collected to measure plasma levels of NDI -034858 as fol lows:  
â€¢ On Day 1 prior to dosing and 1 hour ( Â± 5 min) postdosing; 
â€¢ At Week 4 prior to dosing, 1 hour ( Â± 5 min) postdosing, and 4 hours ( Â± 10 min) 
postdosing; 
â€¢ At Week 8  prior to dosing; 
â€¢ At Week 12 anytime (no study treatment administration at this visit) . 
â€¢ At ET visit anytime (if ET visit is planned before Week 12 visit).  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
72 of 94 The actual date and time of each blood sample collection will be recorded . Details about the 
collection , processing, handling, storage, and shipping of plasma samples will be provided in the 
laboratory manual. 
8.3.7.  
 
 
 
.  
8.3.8.  
 
  
 
 
. 
8.3.9.  
 
 
 
 
 
 
 
 
 
. 
8.3.10.  
 
 
. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
73 of 94 8.3.11. Medical Photography 
Medical photographs will be performed in a subset of subjects who consent to the procedure  at 
the visits specified in  Table  1.  
Photographs will be identified as follows: study number, subject number, visit name, and date. 
Photographs will be uploaded and stored on a secured clinical website and will be transmitted to 
the sponsor for review. Additional information will be provided in the study reference manual. 
8.3.11.1. Medical Photography - Biopsies  
Investigator- selected target plaque areas will be biopsied. These target areas should be 
documented in the subject record and EDC, and the same targeted plaque areas should be 
followed throughout the study. All biopsied areas will be photographed prior to biopsy. 
Care will be taken to use the same camera, the same magnification, and the same settings for 
each photograph at each visit in order to obtain comparable pictures. Medical photographs will be taken using a blue background. 
8.3.11.2. Medical Photography- Full Body Front and Back 
For full body photographs, all study photographs will be captured using the equipment, supplies, 
and guidelines provided by the sponsor or sponsors vendor.
 
Medical photographs, full body front and back, will be performed at selected study sites , in a 
subset of subjects who give written informed consent to the procedure, at the visits specified in  
Table 1. The full body photographs consist of four captures which include the upper posterior/anterior from the neck down and lower anterior/posterior from the toes up.  
8.4. Adverse Events and Serious Adverse Events  
8.4.1. Definition of Adverse Event   
An AE is any untoward medical occurrence in a subject administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or 
disease temporally associated with the use of a study product, whether or not considered related 
to the study product. 
8.4.2. Definition of Serious Adverse Event   
A SAE  is any untoward medical experience occur ring at any dose that res ults in  any of the 
following consequences:  
â€¢ Results in death  
â€¢ Is life -threatening 
â€¢ Requires in -patient hospitalization or prolongation of existing hospitalization 
â€¢ Results in persistent or significant disability/incapacity  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
74 of 94 â€¢ Is a congenital anomaly/birth defect 
â€¢ Is an i mportant medical event that may not be immediately life -threatening or result 
in death or hospitalisation but may jeopardize the subject or may require intervention 
to prevent one of the other outcomes listed above (according to medical judgment of 
the investigator). 
Note: The term â€œlife -threateningâ€ in the definition of â€œseriousâ€ refers to an event in which the 
subject was at risk of death at the time of the event; it does not refer to an event that hypothetically might have caused death if it were more severe.  Medical and scientific judgment 
should be exercised in deciding whether expedited reporting is appropriate in other situations, such as important medical events that may not be immediately -life-threatening  or result in death 
or hospitalization but may jeopardize the subject or may require intervention to prevent one of 
the other outcomes listed in the definition above. These should also usually be considered 
serious . 
Examples of such events are intensive treatment in an emergency r oom or at home for allergic 
bronchospasm, blood dyscrasia, convulsions that do not result in hospitalization,  or development 
of drug dependency or drug abuse. 
Scheduled hospitalization s or elective surgical procedures will not be considered SAEs. 
Prolongation of a scheduled hospitalization can be considered an SAE.  
8.4.3. Classification of an Adverse Event 
8.4.3.1. Relationship to Study Treatment  
The investigator will assess causal  relationship between each reported AE or SAE , and  the 
experimental treatment. The investigator should consider the subjectâ€™s medical history , most 
recent physical examination findings, and concomitant medications.  
The following definitions will be used to determine the causality of an AE  or SAE :  
â€¢ Not related: Temporal relationship of the onset of the AE or SAE , relative to the 
experimental treatment, is not reasonable, or another cause can explain the occurrence 
of the AE. 
â€¢ Related: Temporal relationship of the onset of the AE or SAE , relative to the 
experimental treatment, is reasonable, follows a known response pattern to the 
treatment, and an alternative cause is unlikely.  
8.4.3.2. Adverse Event Severity  
The severity  of an AE or SAE  is an estimate of the relative intensity  of the event made by the 
investigator based on his or her clinical experience and familiarity with the literature. The following definitions from the National Cancer Institute (NCI) CTCAE, Version 5.0, published 
27-Nov-2017 are to be used to rate the sever ity of an AE or SAE : 
â€¢ Grad e 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations 
only; intervention not indicated. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
75 of 94 â€¢ Grade 2: Moderate ; minimal, local or non-invasive intervention indicated; limiting 
age-appropriate instrumental activities of daily living ( ADL )*. 
â€¢ Grade 3: Severe or medically significant but not immediately life -threatening; 
hospitalization or prolongation of hospitalization indicated; disabling; limiting 
selfcare ADL**.  
â€¢ Grade 4 : Life -threatening consequences; urgent intervention indicated.  
â€¢ Grade 5 : Death related to AE.  
Note: A Semi -colon indicates â€˜orâ€™ within the description of the grade.  
*Instrumental ADL refer to preparing meals, shopping for groceries or clothes, using the telephone, managing money, etc. 
**Self -care ADL refer to bathing, dressing and undressing, feeding self, using the toilet, taking 
medications, and not bedridden. 
Changes in severity should be documented in the medical record to allow assessment of the 
durati on of the event at each level of severity. Adverse events characterized as intermittent 
require documentation of the start and stop of each incidence.  
When changes in the severity of an AE occur more frequently than once a day, the maximum 
severity for th e experience that day should be noted. If the severity category changes over several  
days, then those changes should be recorded separately (with distinct onset dates). 
8.4.4. Time Period and Frequency for Event  Assessment and Follow- Up 
The occurrence of an AE or  SAE may come to the attention of study personnel during study 
visits and interviews of a study subject presenting for medical care, or upon review by a study 
monitor. 
All AEs, including local and systemic reactions, will be captured on the appropriate eCR F. 
Information to be collected includes event description, date of onset, clinicianâ€™s assessment of 
severity, relationship to study product (assessed only by those with the training and authority to 
make a diagnosis), and date of resolution/stabilization of the event. All AEs occurring while on study must be documented appropriately regardless of relationship.  
Study site personnel will note the occurrence and nature of each subjectâ€™s medical condition(s) 
present prior to dosing on Day 1  in the appropriate section of the source document and eCRF. 
Starting  at dosing on Day 1, site personnel will note any change in the condition(s) and the 
occurrence and nature of any AE.  
Any medical condition that is present prior to dosing on Day 1  will be considered as part of 
medical history and not reported as an AE. However, if the study subjectâ€™s condition deteriorates 
after dosing on Day 1, it will be recorded as an AE.  
Should a subject experience an AE at any time after dosing on Day 1  until the end of 
participation in the study, the event will be recorded as an AE in the source document and eCRF. 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
76 of 94 Of note, a ny SAE related to  the study participation (eg, screening procedure) will be recorded in 
the source document and eCRF from dosing on Day 1  until the end of participation in the study. 
The investigator is responsible for appropriate medical care of subjects during the study. The 
investigator also remains responsible for following through with an appropriate health care option for all AEs that are ongoing at the end of the study. If an AE is ongoing at the end of 
study, the follow-up duration is left to the discretion of the investigator. Follow-up frequency 
will be performed at the discretion of the investigator . However, in case of an SAE, the subject 
should be followed until the event is resolved or stabilized  as per the investigatorâ€™s judgment . 
8.4.5. Adverse Event Reporting  
Inves tigators are responsible for monitoring the safety of subjects who are participating in this 
study and for alerting the sponsor to any event that seems unusual, even if this event may be considered an unanticipated benefit to the subject.  
8.4.6. Serious Adverse Event Reporting  
 All SAEs, related to the experimental treatment or not, occurring during the study (from dosing 
on Day 1  to last study visit) must be reported on an SAE form to the sponsor-delegated vendor 
(see below contact information) within 24 hours of the knowledge of the occurrence (this refers 
to any AE that meets one or more of the aforementioned serious criteria). When applicable, 
follow-up information should be reported to the sponsor-delegated vendor in the same manner as 
the original SAE report . 
The SAE reporting period ends at the end of the follow-up period. 
Reporting should be done by sending the completed SAE form to the following e- mail address 
(faxing can also be done as a second option in case e- mailing is not possible).  
Safety Contact Information: Innovaderm Drug Safety unit  E-mail: drugsafety@innovaderm.com 
Fax: (514) 221-4199 
Further to the determination of expedited criteria, t he sponsor and delegate will manage the 
submission of individual case safety report to conce rned regulatory agencies in accordance with 
local laws and regulations.  
8.4.7. Adverse Events of Special Interest  
The following are AESI :  
â€¢ CTCAE Grade â‰¥ 2 c ytopenia (anemia, leukopenia, neutropenia, lymphopenia, or 
thrombocytopenia ; clinically significant or not) defined by the following ranges:  
âˆ’ Hemoglobin < 10.0 g/dL (< 100.0 g/L). 
âˆ’ White blood cell count < 3.0 x 10
9/L (< 3000/mm3). 
âˆ’ Absolute neutrophil count of < 1.5 x 109/L (< 1500/mm3). 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
77 of 94 âˆ’ Absolute lymphocyte count of < 0.8 x 109/L (< 800/mm3). 
âˆ’ Platelet count < 75 x 109/L (< 75000/mm3). 
â€¢ CTCAE Grade â‰¥ 3 elevation of CPK (clinically significant or not) defined as CPK > 
5x ULN  
â€¢ Major adverse cardiovascular events, defined as cardiovascular death, nonfatal 
myocardial infarction, and nonfatal stroke 
â€¢ Thromboembolic events, defined as pulmonary embolism, deep vein thrombosis, and 
other venous and arterial thromboembolic events (eg, noncardiac, non-neurologic, fatal and nonfatal)  
â€¢ Gastrointestinal perforation  
â€¢ Malignancies  
â€“ All malignancies  
â€“ Non-melanoma  skin cancer (NMSC) 
â€“ Malignancy excluding NMSC 
â€“ Lymphoma 
â€¢ Infections  
â€“ All infections  
â€“ Serious infection 
â€“ Opportunistic infection, excluding tuberculosis and herpes zoster 
â€“ Herpes zoster  
â€“ Active tuberculosis 
â€¢ Adverse events of abnormal liver function tests 
â€¢ Adverse events of renal dysfunction 
Adverse events of special interest should be reported beginning  on Day 1  after the first dose of 
study drug  using the procedures detailed in Section  8.4.6. If an AESI does  not meet  any 
seriousness criteria, it must still be reported according to the SAEs reporting procedures for 
initial and follow -up reporting, but an AESI form would be used. 
As per Section  7.1, if a subject experiences a CTCAE Grade â‰¥2 cytopenia (anemia, leukopenia, 
neutropenia, lymphopenia, and thrombocytopenia; clinically significant or not) as defined in 
Section  8.4.7 , dosing will be interrupted, and the subject followed with periodic testing until the 
laboratory values return to normal range. If the same subject develops a CTCAE Grade â‰¥2 
cytopenia for a second time after dosing is resumed, then the subject will be permanently 
discontinued from treatment, but may be continued in the trial, and followed until resolution of 
the adverse events.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
78 of 94 Immediate Reporting of AESI  
1. Adverse events of special interest should be reported beginning on Day 1 after the first 
dose of study drug.  The study site must formally notify the sponsor-delegated vendor 
within 24 hours of knowledge of the occurrence.  
2. Even if an AESI does not meet any seriousness criteria, it must still follow the SAEs 
reporting procedures for initial and follow-up reporting ( Section  8.4.6); however, an 
AESI form will be used. 
3. All AESIs must be reported to the sponsor-delegated vendor within 24 hours of 
knowledge of the occurrence regardless of the following: 
4.  Whether or not the subject has undergone study- related procedures  
5. The severity of the event  
6. The relationship of the event to study drug 
7. Refer to the Study Reference Manualâ€™s Official Study Contact List for complete contact 
information to report initial or follow -up information on an AESI.  
8.4.8. Potential Drug Induced Liver Injury  
Alanine aminotransferase or AST values â‰¥ 3 times the ULN  will trigger the following actions 
and evaluations:  
â€¢ The medical monitor should be contacted immediately; 
â€¢ Liver tests including ALT, AST, total bilirubin , and alkaline phosphatase will be 
repeated from the original blood sample as soon as possible, and no longer that 72 hours after originally reported. 
The following combination of signs, symptoms, or laboratory values (based on the original values, not the repeat), require at least temporary discontinuation of the study medication while workup is ongoing: 
â€¢ ALT or AST â‰¥ 3 times the ULN and total bilirubin > 2 times the ULN in the presence of normal alkaline phosphatase; 
â€¢ ALT or AST â‰¥ 8 times the ULN, regardless of other parameters;  
â€¢ ALT or AST > 3 times the ULN with the appearance of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, fever, rash, and/or eosinophilia (>5%). 
ALT or AST values â‰¥ 3 times the ULN but < 8 times the ULN without total bilirubin > 2 times the ULN or the presence of fatigue, nausea, vomiting, right upper quadrant pain or tenderness, 
fever, rash, and/or eosinophilia (>5%) do not require discontinuation of study treatment while workup is ongoing. Nonetheless, a subject may have dosing held based on investigatorâ€™s medical judgement. Temporary discontinuation of study treatment may or may not lead to permanent 
discontinuation pending results of further workup and the overall clinical assessments. The 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
79 of 94 frequency of monitoring liver tests or relevant laboratory tests will be decided as part of the 
consultation between the investigator and medical monitor. 
The medical monitor will work with the investigator to evaluate other possible causes of the 
observed liver test abnormalities. These other possible causes could include hepatitis (viral, 
alcoholic, or autoimmune); hepatobiliary disorders; nonalcoholic steatohepatitis ; cardiovascular 
causes; and other concomit ant treatments ( https://www.fda.gov/regulatory- information/search -
fda-guidance-documents/drug-induced- liver-injury- premarketing -clinical -evaluation ). 
8.4.9. Pregnancy Reporting  
If a female subject becomes pregnant after dosing on Day 1 during the study and up to 4 weeks 
after the end of the study, or if a female partner of a male subject  becomes pregnant after male 
subject dosing on Day 1 during the study and up to 12 weeks after the end of the study, the subject should inform the study site as soon as possible. Upon confirmation of the pregnancy, the 
female subject will be  permanently discontinued from the study treatment , if this occurs before 
the end of dosing period. The investigator must complete a study specific pregnancy form upon 
confirmation of a pregnancy and report it to the sponsor-delegated vendor within 24 hours of 
confirmation of the pregnancy (contact information to be used is the same as for SAE reporting). 
All cases of pregnancy will be report ed to the sponsor-delegated vendor in a timely manner  using 
the Preg nancy Form . Pregnancy is not itself an AE or SAE; however, maternal/fetal 
complications or abnormalities will be recorded as AEs or SAEs, as appropriate. The investigator will follow the p regnancy until completion or until pregnancy termination and, in the case of a 
live-born offspring, to 1 month of age in that infant. Congenital abnormalities and birth defects 
in the offspring of male or female subjects should be reported as an SAE if conception occurred during the study drug period, or within 5 times the half -life or 12 weeks from their last dose of 
study drug, whichever is longer. The investigator will notify the pharmacovigilance unit of the 
outcome as a follow-up to the initial pregnancy form. All pregnancies should be reported to the 
sponsor and, when applicable, to the ethics committee. 
8.4.10. Overdose  
Study product overdose is any accidental or intentional use of study product in an amount higher 
than the dose indicated per protocol for a given subject. Study product compliance (see 
Section  6.3.2) should be reviewed to detect potential instances of overdose (intentional or 
accidental) . 
Any study product overdose during the study should be recorded on the source document and eCRF. In the event of overdose, the subject should be closely monitored for any potential AEs. All AEs associated with an overdose should be entered on the Adverse Event eCRF and reported 
using the procedures detailed in S ection  8.4.6, Serious Adverse Events Reporting, even if the 
events do not meet seriousness criteria. If the AE associated with an overdose does not meet seriousness criteria, it must still be reported using the SAEs reporting procedures, but an 
overdose form would be used. The excess quantity and duration of the overdose should be 
recorded.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
80 of 94 9. STATISTICAL CONSIDERATIONS  
9.1. Sample Size  Determination  
The sample size determination is based on testing equality of two independent response rates 
using a 2-sided test with significance level of alpha = 0.05 and power 85%. The formula used for the calculation is the same as used in the nQueryÂ® (ie, normal approximation with Fleissâ€™ formula and continuity correction). 
Assuming the placebo response rate at end of Week 12 is 10% (proportion of subjects achieving 
PASI -75), at least  one of the NDI-034858 dose treatment groups will have a response rate at 
least 40%, and after adjustment of 15% dropout rate, a total of 250 subje cts (50 per treatment 
group) will be randomized in the study.  
9.2. Populations for Analyses  
Efficacy will be evaluated on the basis of m ITT analysis set . A supportive analysis will also be 
conducted on the PP a nalysis set . 
Intent- to-treat (ITT) analysis set : This analysis set will include all subjects who were 
randomized . All subjects will be analyzed according to the treatment group to which they were 
randomized.  
Modified intent- to-treat (mITT) analysis set : This analysis set will include all subjects who were 
randomized and received at least one dose of study treatment. All subjects will be analyzed 
according to the treatment group to which they were randomized. The mITT analysis set will be 
used as the primary analysis population for efficacy. 
Per-protocol (PP) analysis set : This analysis set will include all subjects who were randomized , 
who received at least one dose of study product, and who provided evaluable data for the primary endpoint with no major protocol deviations affecting the efficacy evaluations. All subjects will be analyzed according to the treatment group that they actually received .
 
Safety  analysis set : This analysis set will include a ll subjects who received at least one dose of 
the study product . All subjects will be analyzed according to the treatment  they received . 
Pharmacokinetic (PK) analysis set : This analysis set  will include all subjects who received at 
least one dose of NDI-034858 and have evaluable plasma concentration data.  
. 
9.3. Statistical Analyses  
9.3.1. General Approach  
Categorical variables will be presented in tables as frequencies and percentages. Continuous 
variables will be summarized in tables and will include the number of subjects, mean, SD , 
median, minimum, and maximum.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
81 of 94 Further details regarding the efficacy and  safety variable definitions, analyses strategy, statistical 
justification, and techniques for handling missing values (if applicable) will be detailed in a 
separate SAP that will be prepared before the database is locked and any analyses are 
undertaken. Any deviation(s) from the SAP will be described and justified in the final Clinical 
Study Report, as appropriate. 
All statistical tests will be two -sided and will be performed with a significant level of 0.05, 
unless otherwise specified in the SAP. To account for the multiplicity testing in the primary 
endpoint analysis, each active treatment group will be compared to the placebo group using a 
hierarchical testing procedure, starting with the highest dose group and ending with the lowest 
dose group (30- mg NDI -034858, 15- mg NDI -034858, 5- mg NDI -034858, and 2- mg NDI -
034858, in order ). No adjustment to alpha will be made to account for multiple testing between 
treatment groups for the secondary  efficacy endpoints.  
9.3.2. Efficacy Analyses 
The primary endpoint can be translated as a responder analysis, where a subject will be classified as responder if he or she achieves PASI -75 at Week 12. The comparison between groups for the 
primary endpoint will be done using a CMH, with prior treatment with biologics included as a 
stratification factor. The primary efficacy analysis will be performed on the m ITT analysis set, 
while the PP analysis set will be used as a sensitivity analysis.  
The secondary endpoints involving proportions of subjects will b e analyzed using the same 
approach (CMH test) as described for the primary efficacy analysis, at each time point and based on the m ITT analysis.  
The continuous secondary endpoints involving absolute change from baseline will be analyzed 
using an MMRM based on the m ITT analysis set only. The model will include treatment, visit, 
treatment  by-visit interaction, and prior treatment with biologics as fixed effects, and baseline 
score as a covariate.  
9.3.3. Safety Analyses 
All safety analyses will be conducted using the safety analysis set. No inferential statistics will be performed on safety variables.  Adverse events  and SAEs will be presented and tabulated 
according to MedDRA  classification  by treatment group. Descriptions of AEs will include the 
start date , the stop date (if it resolved), the severity and seriousness of the AE, the relationship  of 
the AE to study product, action taken with respect to the study product and the outcome. 
Reported AEs will be summarized by the number of subjects reporting the events, as w ell as by 
system organ class, preferred term , reported verbatim severity, seriousness, and investigatorâ€™s 
assessment of the relationship to study product. For the summary of AEs by severity, each 
subject will be counted only once within a system organ class or a preferred term by using the 
AEs with the highest intensity within each category for each analysis. For the summary of AEs 
by relationship to study product, each subject will be counted only once within a system organ 
class or a preferred term by using the AEs with the greatest reported relationship within each 
category. For the summary of AEs by relationship to study product and severity, each subje ct 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
82 of 94 will be counted only once within a system organ class or a preferred term by using (1) the 
greatest reported relationship followed by (2) the highest reported intensity. 
All information pertaining to AEs noted during the study will be listed by treatment group, 
subject, detailing verbatim, system organ class, preferred term , start date, stop date, intensity, 
outcome, action taken with respect to study product, and relationship to study product. The AE 
onset will also be shown relative (in number of days) to the day of study product administration. 
Serious adverse events will be tabulated by treatment group, relationship to the test article, and a reference to the occurrence of the SAEs to the relative day of dosing. Similar listings will be provided for the SAEs and AEs leading to the discontinuation from the study. 
Results from vital signs, laboratory analyses , and  ECGs  will be tabulated by treatment and visit 
using descriptive statistics. The observed value at each visit, as well as the change from baseline 
will be presented. Shift tables describing shifts to out-of-normal range will be provided for 
clinical laboratory results , and normal to abnormal shift tables may  be provided for vital signs. 
Concomitant medications will be coded with the WHO -DD and listed by subject. Summary of 
medication classes will also be tabulated.  
9.3.4. Pharmacokinetic Analyses  
Concentration data will be listed per subject and summarized descriptively per dose.  
9.3.5.  
. 
9.3.6. Other Analyses  
Descriptive summaries of subject disposition and baseline charact eristics  (including 
demographic data and prior concomitant therapy) will be presented  by treatment group. In 
addition, a list of subjects who discontinued from the study along with discontinuation reason will be provided. 
Protocol deviations will be summarized by treatment and category. 
9.3.7. Planned Interim Analys es 
No interim analysis is planned in this study.  
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
83 of 94 10. REGULATORY, ETHICAL, AND STUDY OVERSIGHT 
CONSIDERATIONS  
10.1. Local Regulations/Declaration of Helsinki  
This study will be conducted in accordance with the ethical principles that have their origin in 
the Declaration of Helsinki and that are consistent w ith ICH Tripartite Guideline for GCP and 
the applicable laws  and regulations of the country in which the research is conducted, whichever 
affords the greater protection to the individual. 
10.2. Ethical Review  
It is the understanding of the sponsor that this protocol (and any amendments) as well as appropriate consent procedures, will be reviewed and approved by an IRB/REB . This board must 
operate in accordance with the current federal regulations. For sites with a local ethics 
committee, a letter or certification of approval will be sent by the investigator to the sponsor (or 
CRO) before initiation of the study and  whenever subsequent modifications to the protocol are 
made.  
10.3. Informed Consent Process  
An ICF descri bing in detail the study treatment, study procedures, and risks will be given to the 
subject, along with an assent form when required. 
It is the responsibility of the investigator, or a person designated by the investigator (if 
acceptable by local regulati on), to obtain written informed consent from each i participa nt in this 
study, after adequate explanation of the aims, methods, objectives, and potential hazards of the 
study. 
Informed consent is a process that is initiated prior to the individualâ€™s agreeing to participate in 
the study and continues throughout the individualâ€™s study participation. Consent forms will be IRB/REB  approved, and the subject will be asked to read and review the document. The 
investigator will explain the research study to the subject and answer any questions that may arise. A verbal explanation will be provided in terms suited to the subjectâ€™s comprehension of the purposes, procedures, and potential risks of the study and of his or her rights as a research 
subject. Subjects will h ave the opportunity to carefully review the written consent form and ask 
questions prior to signing. The subjects should have the opportunity to discuss the study with 
their family or surrogates or think about it prior to agreeing to participate. 
The subject will sign the informed consent document prior to any procedures being done 
specifically for the study. Subjects must be informed that participation is voluntary and that they may withdraw from the study at any time for any reason, without prejudice. A copy of the signed 
informed consent document will be given to the subjects for their records. The informed consent 
process will be conducted and documented in the source document (including the date), and the form signed before the subject undergoes any study- specific procedures.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
84 of 94 The rights and welfare of the subjects will be protected by emphasizing to them that the quality 
of their medical care will not be adversely affected if they decline to participate in this study.  
If new safety information results in significant changes in the risk/benefit assessment, or if any new information becomes available that may affect the willingness of a subject to continue to participate, the consent form should, if necessary, be reviewed and updated by the IRB /REB . All 
subjects (including those already being treated) should be informed of the new information, given a copy of the revised form, and asked to give their consent to continue in the study. 
10.4. Study Discontinuation and Closure  
This study may be temporarily suspended or prematurely terminated if there is sufficient 
reasonable cause. Written notification documenting the reason for study suspension or 
termination will be provided by the suspending or terminating party to study subjects, investigators, the sponsor, and regulatory authorities. If the study is prematurely terminated or 
suspended, the principal investigators will promptly inform study subject s and  the IRB /REB  and 
will provide the reason(s) for the termination or suspension. Study subjects will be contacted, as 
applicable, and be informed of changes to the study visit schedule. 
Circumstances that may warrant termination or suspension of the study include, but are not 
limited to the following:  
â€¢ Determination of unexpected, significant, or unacceptable risk to subjects 
â€¢ Insufficient compliance with protocol requirements 
â€¢ Data that are not sufficiently complete or evaluable 
â€¢ Scientific or corporate reasons  
The study may resume once concerns about safety, protocol compliance, and data quality are addressed and  satisfy the sponsor, IRB /REB , Health Canada, and/or FDA.  
10.5. Confidentiality and Privacy  
Subject confidentiality and privacy are  strictly held in trust by the participating investigators, 
their staff, and the sponsor and their interventions. C onfidentiality is extended to cover testing of 
biological samples in addition to the clinical information relating to subjects. Therefore, the study protocol, documentation, data, and all other information generated will be held in strict confidence. 
The investigator mus t assure that the subjectsâ€™ anonymity will be maintained , and that subjectsâ€™ 
identities are protected from unauthorized parties. On case report forms  or other documents 
submitted to the sponsor, subjects should not be identified by their names, but by an 
identification code. The investigator should keep a subject log relating codes with the names of 
subjects. The investigator should maintain in strict confidence documents not for submission to Nimbus Lakshmi, Inc. (eg, subjectsâ€™ written consent forms). 
All research activities will be conducted in a setting as private as possible.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
85 of 94 The study monitor, other authorized representatives of the sponsor, and representatives of the 
IRB, regulatory agencies, or pharmaceutical company supplying study product may inspec t all 
documents and records required to be maintained by the investigator, including but not limited to, medical records (office, clinic, or hospital) and pharmacy records for the subjects in this study. The clinical study site  will permit access to such r ecords.  
The study subjectâ€™s contact information will be securely stored at each clinical site for internal use during the study. At the end of the study, all records will continue to be kept in a secure location for as long a period as dictated by the applicable legal or regulatory requirements, the reviewing IRB, institutional policies, or sponsor requirements. 
10.6. Clinical Monitoring  
Clinical site monitoring will be conducted to ensure that the rights and well-being of study subjects are protected; that the r eported study data are accurate, complete, and verifiable; and 
that the conduct of the study is following  the currently approved protocol/amendment(s), ICH 
GCP guidelines, and with applicable regulatory requirement(s). Details of clinical site monitoring w ill be  documented in a Monitoring Plan. 
Centralized monitoring, which consists of remote review of accumulating data from all sites, will be performed as detailed in the Centralized Monitoring Plan. 
10.7. Quality Assurance and Quality Control  
Each clinical site will perform internal quality management of study conduct, data and biological 
specimen collection, documentation, and completion. 
Quality control (QC) procedures will be implemented beginning with the data entry system, and 
data QC checks, which will be run on the database, will be generated. Any missing data or data anomalies will be communicated to the site(s) for clarification/resolution.  
During the study, the sponsor or its representative will conduct monitoring visits at regular intervals. The monitoring visits will be conducted to ensure protocol adherence, quality of data, accuracy of entries on the eCRFs , study product accountability, compliance with regulatory 
requirements, and continued adequacy of the study site and its facilities.  
The site may be audited, monitored, or inspected by a quality assurance officer named by the 
sponsor, by the REB or IRB, and/or by the regulatory authorities. The investigator will be 
expected to cooperate with any audit and provide assistance and documentation (including 
source data) as requested. The study site will provide direct access to all study- related sites, 
source data/documents, and reports for the purpose of monitoring and auditing by the sponsor and inspection by local and regulatory authorities. 
10.8. Data H andling and Record Keeping  
Data collection is the responsibility of the clinical study staff at the site under the supervision of 
the site investigator. The investigator is responsible for ensuring the accuracy, completeness, legibility, and timeliness of the data reported.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
86 of 94 The investigator must maintain adequate and accurate records to enable the conduct of the study 
to be fully documented and the study data to be subsequently verified. These documents should 
be classified into two separate categories: inv estigatorâ€™s study files and subject clinical source 
documents. 
The investigator must maintain source documents for each subject in the study. These source 
documents will consist of case and visit notes (clinical medical records) containing demographic 
and medical information and the results of any tests or assessments. All information on the eCRF s must be traceable to the source documents in the subjectâ€™s file. Data not requiring a 
written or electronic record will be defined before study start and will be recorded directly on the eCRFs , which will be documented as being the source data. 
The records should be retained by the investigator according to ICH guidelines, local regulations, or as specified in the Clinical Trial Agreement, whichever retention perio d is longer. 
Subject data will be entered by site personnel using Medrio, a web -based EDC  and reporting 
system. This application will be set up for remote entry. Medrio  is the developer and owner of 
Medrio . The EDC software has been fully validated and conforms to Title 21 of the Code of 
Federal Regulations, Part 11 requirements. Investigator site staff will not be given access to the EDC system until they have been fully trained. Designated investigator staff will enter the data 
required by the protocol into the eCRFs using this web-based application. Automatic validation 
programs check for data discrepancies in the eCRFs and, by generating appropriate error messages, allow modification or verification of the entered data by the investigator staff before 
confirming the data. The investigator must certify that the data are complete and accurate by 
applying an electronic signature to the eCRFs.  
The data collected will be encoded and stored electronically in a database system. Validated data may subsequently be transferred to the sponsor. 
10.9. Protocol Deviations 
A protocol deviation is any noncompliance with the clinical study protocol requirements. The noncompliance may be either on the part of the subject, the investigator, or the study site staff. 
As a result of deviations, corrective actions are to be developed by the site and implemented 
promptly. The study monitor must ensure that prompt action is taken to secure compliance. If a 
noncompliance that significantly affects or has the potential to significantly aff ect human subject 
protection or reliability of study results is discovered, a root cause analysis will be performed , 
and appropriate corrective and preventive actions will be implemented . 
Protocol deviations must be sent to the reviewing IRB per their policies. The investigator is 
responsible for knowing and adhering to the reviewing IRB requirements. 
10.10.  Publication Policy  
The publication policy will be addressed in the Research and Financial Agreement, and all details outlined in the agreement will apply to this protocol. The study will be registered on 
ClinicalTrials.Gov prior to the first subject being dosed.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
3URWRFRO1XPEHU
3URWRFRO9HUVLRQ)HE
&RQILGHQWLDO
RI 5()(5(1&(6
 5HQGRQ$6FKDNHO.3VRULDVLV 3DWKRJHQHVLVDQG7UHDWPHQW ,QW-0RO6FL 
 .UXHJHU-*%UXQQHU30,QW HUOHXNLQDOWHUVWKHELRORJ\RI PDQ\FHOOW\SHVLQYROYHGLQ
WKHJHQHVLVRISVRULD VLVV\VWHPLFLQIOD PPDWLRQDQGDVVRFLDWHG FRPRUELGLWLHV ([S
'HUPDWRO 
 2ML9/XJHU7$7KHVNLQLQSV RULDVLVDVVHVVP HQWDQGFKDOO HQJHV&OLQ([S5KHXPDWRO
6XSSO6
 *UHE-(*ROGPLQ]$0(O GHU-7HWDO3VRULDVLV 1DW5HY'LV3ULPHUV 
 0HQWHU$6WUREHU%(.DSODQ '+HWDO-RLQW$$'13)JXLGHO LQHVRIFDUHIRUWKH
PDQDJHPHQWDQGWU HDWPHQWRISVRULDVLVZLWKELRORJLFV -$P$FDG'HUPDWRO

 0HQWHU$.RUPDQ1-(OPHWV& $HWDO*XLGHOLQHVRIFDUHIR UWKHPDQDJHPHQWRI
SVRULDVLVDQGSVRULD WLFDUWKULWLVVHFWL RQ*XLGHOLQHVRIFDU HIRUWKHPDQDJHPHQWDQG
WUHDWPHQWRISVRULDVLVZLWKWUD GLWLRQDOV\VWHPLFDJHQWV -$P$FDG'HUPDWRO

 &URZOH\-7KDFL'-RO\3H WDO/RQJWHUPVDIHW\DQGWROH UDELOLW\RIDSUHPLODVWLQ
SDWLHQWVZLWKSVRULDVL V3RROHGVDIHW\DQDO\VLVIRU! ZHHN VIURPSKDVH
UDQGRPL]HGFRQWUROOHGWULDOV(67((0DQG -$P$FDG'HUPDWRO 
H
 9DQJLSXUDP5$OLNKDQ$$SUHPLOD VWIRUWKHPDQDJHPHQWRIPR GHUDWHWRVHYHUHSODTXH
SVRULDVLV ([SHUW5HY&OLQ3KDUPDFRO 
 :DWIRUG:7+LVVRQJ%'%UHDP -+.DQQR<0XXO/2
6KHD-- 6LJQDOLQJE\,/
DQG,/DQGWKHLPPXQRUH JXODWRU\UROHVRI67$7 ,PPXQRO5HY 
 6WDUN*5'DUQHOO-(-U7KH -$.67$7SDWKZD\DWWZHQW\ ,PPXQLW\ 

 6XWWRQ&(0LHONH/$0LOOV .+,/SURGXF LQJJDPPDGHOWD 7FHOOVDQGLQQDWH
O\PSKRLGFHOOV (XU-,PPXQRO 
 3DSS.*RUGRQ.7KDFL'HWDO 3KDVH7ULDORI6HOHFWLY H7\URVLQH.LQDVH,QKLELWLRQ
LQ3VRULDVLV 1(QJO-0HG 
 $UPVWURQJ$(IILFDF\DQG6DI HW\RI'HXFUDYDFLWLQLEDQ2UDO 6HOHFWLYH7\URVLQH.LQDVH
7<.,QKLELWRU&RPSDUHG: LWK3ODFHERDQG$S UHPLODVWLQ0RG HUDWHWR6HYHUH
3ODTXH3VRULDVLV5HVXOWV)URP WKH3KDVH32(7<.3626WXG\ 3UHVHQWHGDWWKH
$PHULFDQ$FDGHP\RI'HUPDWRO RJ\9LUWXDO0HHWLQJ([SHULHQFH $$'90;
9LUWXDO


 )UHGULNVVRQ73HWWHUVVRQ86HY HUHSVRULDVLVRUDOWKHUDS\ ZLWKDQHZUHWLQRLG
'HUPDWRORJLFD 
 /DQJOH\5*)HOGPDQ651 \LUDG\-YDQGH.HUNKRI33DSDYD VVLOLV&7KHSRLQW
,QYHVWLJDWRU
V*OREDO$VVHVVPHQ W,*$6FDOH$PRGLILHGWRROI RUHYDOXDWLQJSODTXH
SVRULDVLVVHYHULW\L QFOLQLFDOWULDOV -'HUPDWRORJ7UHDW 'RFX6LJQ(QYHORSH,'')')%)$&
PPD)RUQRQFRPPHUFLDOXVHRQO\GWROHUDEWROHUD
 ZHZ
-$P$-$P
WKHPDQDKHPD

.DQQR.DQQ
U\UROHV\UROH
$..67$67$
LOOV.+OV.+
PPXQROPXQR
7KDFL'7KDFL'
0HG0
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
88 of 94 17.  
. 
18.  
. 
19.  
 
. 
20.  
 
. 
21. Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) --a simple practical 
measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-216. 
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
89 of 94 APPENDIX  1. PARTIAL LIST OF STRONG OR MODERATE  
INHIBITORS OF CYP3A4 
 
CYP3A4 Inhibitors  
Strong*  Moderate  
boceprevir  aprepitant  
clarithromycin  ciprofloxacin  
cobicistat  conivaptan  
idelalisib  crizotinib  
itraconazole  cyclosporine  
ketoconazole  diltiazem  
nefazodone  dronedarone  
nelfinavir  erythromycin  
posaconazole  fluconazole  
ritonavir or any combination medication 
containing ritonavir  fluvoxamine  
telaprevir  imatinib  
telithromycin  tofisopam  
troleandomycin  verapamil  
voriconazole   
*Grapefruit juice is also considered a strong inhibitor of CYP3A4. Please refer to Exclusion 
Criteria 31 for restrictions on grapefruit or grapefruit juice consumption. 
Note: Strong and moderate inhibitors are drugs that increase the AUC of sensitive index substrates of a given metabolic pathway â‰¥5-fold and â‰¥2 to <5-fold, respectively. 
Adapted from : 
https://www.fda.gov/drugs/drug- interactions -labeling/drug-development-and-drug- interactions -
table -substrates -inhibitors- and-inducers; accessed 7 Apr 2021 
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
90 of 94 APPENDIX  2. PSORI ASIS AREA AND SEVERITY INDEX  
 
PASI Scoring  
Four anatomic sites â€”head, upper extremities, trunk, and lower extremities â€”are assessed for 
erythema, induration/infiltration  (plaque thickness), and desquamation (scaling), as seen on the 
day of the examination. The severity of each sign is assessed using a 5- point scale:  
â€¢ 0 = no symptoms 
â€¢ 1 = slight 
â€¢ 2 = moderate  
â€¢ 3 = marked  
â€¢ 4 = very marked  
The area affected by psoriasis within a given anatomic site is estimated as a percentage of the 
total area of that anatomic site and assigned a numerical value according to the degree of psoriatic involvement as follows: 
â€¢ 0 = no involvement 
â€¢ 1 = <10% 
â€¢ 2 = 10% to < 30% 
â€¢ 3 = 30% to < 50% 
â€¢ 4 = 50% to < 70% 
â€¢ 5 = 70% to < 90% 
â€¢ 6 = 90% to 100% 
Assignments for the following body regions are as follows: 
â€¢ Neck: include with the head . 
â€¢ Buttocks: include with the lower extremities . 
â€¢ Axillae: include with the trunk . 
â€¢ Genitals: include with the trunk . 
â€¢ The inguinal canal separates the trunk and legs anteriorly . 
The PASI score for each body region is obtained by using the formula below:  
PASI = 0.1 ( E
h + I h + D h) Ah + 0.2 (E u + I u + Du) Au + 0.3 (E t + It + Dt) At + 0.4 (E l + Il + Dl) Al 
Where E, I, D, and A denote erythema, induration, desquamation, and area, respectively, and h, u, t, and l denote head, upper extremities, trunk, and lower extremities, respectively.  
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
91 of 94 APPENDIX  3.  
 
.   
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Protocol Number 4858- 201 
Protocol Version 3.0: 04-Feb-2022  
 
Confidential 
92 of 94 APPENDIX  4.  
 
.   
 
 
 
 
DocuSign Envelope ID: 4194D198-F02D-4229-8F23-73031B7F0AC2
For non-commercial use only
Pr ot oc ol N u m ber 4 8 5 8 -2 0 1  
Pr ot oc ol Versi o n 3. 0: 0 4 -Fe b -2 0 2 2  
 
C o nfi de ntial 
9 3 of 9 4 A P P E N DI X  5.  D E R M A T O L O G Y LI F E Q U A LI T Y I N D E X  
T he ai m of t his q uesti o n n aire is t o me as ure h o w m uc h y o ur s ki n pr o ble m h as affecte d y o ur life 
O V E R T H E L A S T W E E K. Ple ase c hec k o ne b o x f or e ac h q uesti o n.  
1. O ver t he last wee k, h o w itc h y , s ore , p ai nf ul  or sti n gi n g  has 
y o ur s ki n bee n?  Ver y m uc h  
A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨ 
ï‚¨  
2. O ver t he last wee k, h o w e m b arr asse d  or self -c o nsci o us  ha ve 
y o u bee n beca use of y o ur s ki n?  Ver y m uc h  
A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨ 
ï‚¨  
3. O ver t he last wee k, h o w m uc h has y o ur s ki n i nterfere d wit h 
y o u g oi n g s h o p pi n g  or l o o ki n g after y o ur h o me  or y ar d ? Ver y m uc h  
A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨ 
ï‚¨  
 
 
N ot 
rele va nt  ï‚¨ 
4. O ver t he last wee k, h o w m uc h has y o ur s ki n i nfl ue nce d t he 
cl ot hes  y o u wear?  Ver y m uc h  
A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨ 
ï‚¨  
 
 
N ot 
rele va nt  ï‚¨ 
5. 
 O ver t he last wee k, h o w m uc h has y o ur s ki n affecte d a n y 
s oci al  or leis ure  acti vities?        Ver y m uc h  
A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨ 
ï‚¨  
 
 
N ot 
rele va nt  ï‚¨ 
6. O ver t he last wee k, h o w m uc h has y o ur s ki n ma de it diffic ult 
f or y o u t o d o a n y s p ort ? 
 Ver y m uc h  
A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨ 
ï‚¨  
 
 
N ot 
rele va nt  ï‚¨ 
7 
 O ver t he last wee k, has y o ur s ki n pre ve nte d y o u fr o m w or ki n g  
or st u d yi n g ? Yes  
N o 
 ï‚¨ 
ï‚¨  
N ot 
rele va nt  ï‚¨ 
If â€œ N o ,â€ o ver t he last wee k h o w m uc h has y o ur s ki n bee n a 
pr o ble m at w or k  or st u d yi n g ? A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨  
 
 D o c u Si g n E n v el o p e I D: 4 1 9 4 D 1 9 8- F 0 2 D- 4 2 2 9- 8 F 2 3- 7 3 0 3 1 B 7 F 0 A C 2 
F or n o n- c o m m er ci al u s e o nl y 
Pr ot oc ol N u m ber 4 8 5 8 -2 0 1  
Pr ot oc ol Versi o n 3. 0: 0 4 -Fe b -2 0 2 2  
 
C o nfi de ntial 
9 4 of 9 4 T he ai m of t his q uesti o n n aire is t o me as ure h o w m uc h y o ur s ki n pr o ble m h as affecte d y o ur life 
O V E R T H E L A S T W E E K. Ple ase c hec k o ne b o x f or e ac h q uesti o n.  
8. O ver t he last wee k, h o w m uc h has y o ur  s ki n create d pr o ble ms 
wit h y o ur p art ner  or a n y of y o ur cl ose frie n ds or rel ati ves ? 
   Ver y m uc h  
A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨ 
ï‚¨  
 
 
N ot 
rele va nt  ï‚¨ 
9. O ver t he last wee k, h o w m uc h has y o ur  s ki n ca use d a n y se x u al 
diffic ulties ?   Ver y m uc h  
A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨ 
ï‚¨  
 
 
N ot 
rele va nt  ï‚¨ 
1 0.  O ver t he last wee k, h o w m uc h of a pr o ble m has t he tre at me nt  
f or y o ur s ki n bee n, f or e xa m ple b y ma ki n g y o ur h o me mess y, 
or b y ta ki n g u p ti me?  Ver y m uc h  
A l ot  
A little  
N ot at all  ï‚¨ 
ï‚¨ 
ï‚¨ 
ï‚¨  
 
 
N ot 
rele va nt  ï‚¨ 
Â©A Y Fi nla y, G K K ha n, A pril 1 9 9 2 w w w. der mat ol o g y. or g. u k.  
Ple ase c hec k y o u h a ve a ns were d E V E R Y q uesti o n. T h a n k y o u.  
If t w o or m ore q uesti o ns are left u n a ns were d t he q uesti o n n aire is n ot sc ore d. If t w o o r 
m ore res p o nse o pti o ns are tic ke d, t he res p o nse o pti o n wit h t he hi g hest sc ore s h o ul d be 
rec o r de d. If t here is a res p o nse bet wee n t w o tic k b o xes, t he l o wer of t h e t w o sc o re o pti o ns 
s h o ul d be rec or de d.  D o c u Si g n E n v el o p e I D: 4 1 9 4 D 1 9 8- F 0 2 D- 4 2 2 9- 8 F 2 3- 7 3 0 3 1 B 7 F 0 A C 2 
F or n o n- c o m m er ci al u s e o nl y 